Stem cell therapy for inflammatory bowel disease by Duijvestein, Marjolijn
Stem Cell Therapy for Inflammatory Bowel Disease
Marjolijn Duijvestein
The studies described in this thesis were performed at the Department of Gastroenterology and Hepatology of the Leiden University Medical Center, 
Leiden, the Netherlands.
Layout: Pepijn Duijvestein
Cover photograph: Marjolijn Duijvestein
Cover design: Nina Sickenga
ISBN/EAN: 978-90-818537-0-5
Copyright © 2012 M. Duijvestein, Amsterdam, the Netherlands. All rights reserved. 
No part of this book may be reproduced or transmitted in any form or by any means, without prior written admission of the author. 
Printed by: Haveka, Alblasserdam (www.haveka.nl/greening)
This publication (cover and interior) is printed on recycled paper, Revive?
with ink form renewable resources and alcohol free fountain solution.
         Recycled, EU Flower, FSC, ISCO 14001 
 
Financial support for the publication of this thesis was kindly provided by 
ABBOTT Immunology, Bayer HealthCare Pharmaceuticals, ChipSoft B.V., Dr. Falk Pharma Benelux B.V.
Dutch Digestive Foundation (Maag Lever Darm Stichting), EuroTec B.V., J.E. Jurriaanse Stichting, Ferring B.V.
Merck Sharp & Dohme B.V, Netherlands Society of Gastroenterology (NVGE), Olympus Nederland B.V. 
Section Experimental Gastroenterology (SEG) of the Netherlands Society of Gastroenterology (NVGE), Tramedico B.V. 
Printed by: Haveka, Alblasserd m (www.haveka.nl/greening). This publication 
(cover and interior) is printed on recycl d paper ‘Revive?’ with ink form renewable 
resources and alcohol free fou tain solution. Recycle , EU Flow r, FSC, ISCO 14001 
Stem Cell Therapy for Inflammatory Bowel Disease
Proefschrift
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof. mr. P. F. van der Heijden,
volgens besluit van het College voor Promoties
te verdedigen op donderdag 9 februari 2012
klokke 13.45 uur
door
Marjolijn Duijvestein
geboren te Tegucigalpa (Honduras) 
in 1982
 Promotiecommissie 
Promotor :!! ! ! ! prof. dr. D. W. Hommes
Co-promotores:!  ! ! dr. H. Roelofs
! ! ! ! ! ! ! prof. dr. G.R. van den Brink (Academisch Medisch Centrum, Amsterdam)
Overige leden:! ! ! prof. dr. L. Egan (University of Galway, Galway, Ireland)
! ! ! ! ! ! ! prof. dr. W.E. Fibbe 
! ! ! ! ! ! ! prof. dr. F. Koning 
! ! ! ! ! ! ! prof. dr. C.L. Mummery
! ! ! ! ! ! ! prof. dr. A.J. Rabelink
! ! ! ! ! ! ! dr. P.C.F. Stokkers (Sint Lucas Andreas Ziekenhuis, Amsterdam)


TABLE OF CONTENTS 
Chapter 1!! Introduction 
! ! ! ! Journal of Crohn's and Colitis 2008 Jun;2(2):99-106 and Inflammatory Bowel Disease Monitor 2010;11(2):57–64.
Chapter 2!! Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn`s disease
! ! ! ! Journal of Crohn’s and Colitis 2011 Dec;5(6):543-9.
Chapter 3!! Autologous bone marrow derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phase I study
! ! ! ! Gut 2010;59:1662-1669.
Chapter 4!! Mesenchymal stromal cell function is not affected by drugs used in the treatment of inflammatory bowel disease
! ! ! ! Cytotherapy 2011 Oct;13(9):1066-73.
Chapter 5!! Pretreatment with interferon-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis 
! ! ! ! Stem Cells 2011 Oct;29(10):1549-58.
Chapter 6 ! Summary, discussion, and future perspectives
! !  ! ! Samenvatting, discussie en toekomstperspectieven
Chapter 7!! List of publications
! ! ! ! Curriculum Vitae
! ! ! ! Acknowledgements!
! ! ! ! Abbreviations
9
25
37
53
65
85
89
96
99
100
103
CHAPTER 1
Introduction
Adapted from Journal of Crohn's and Colitis 2008 Jun;2(2):99-106
 and Inflammatory Bowel Disease Monitor 2010;11(2):57–64.
  
Inflammatory bowel disease (IBD) refers to chronic diseases that cause 
inflammation of the intestines. The most common inflammatory bowel 
diseases are ulcerative colitis (UC) and Crohn's disease (CD). These 
disorders have both distinct and overlapping pathologic and clinical 
characteristics. Ulcerative colitis is characterized by recurring episodes of 
inflammation limited to the mucosal layer of the colon. It almost 
invariably involves the rectum and may extend in a proximal and 
continuous fashion to involve other portions of the colon. Crohn's 
disease is characterized by chronic, relapsing transmural inflammation 
and ulceration, and may affect any part of the gastrointestinal tract from 
the oral cavity to the anus, but typically involves the ileum, colon or 
perianal region. Their pathogenesis remains incompletely understood.1
Epidemiology, clinical manifestation and diagnosis
Incidence rates range from 2.2 to 14.3 cases per 100 000 person-years 
for UC and 3.1 to 14.6 cases per 100 000 person-years for CD in 
North America.2 In Europe, the overall incidence per 100 000 person-
years is 5.6.3 Prevalence rates range from 37 to 246 cases per 100 000 
persons for UC and from 26 to 201 cases per 100 000 for CD. IBD can 
present at any age, although the peak incidence occurs between the 
ages of 15 and 30 years.4 There is no gender specificity.
The major symptoms of IBD are abdominal pain, (bloody) diarrhea and 
generalized fatigue. Patients can also experience fever and weight loss. 
Frequent complications of CD are intestinal obstruction, fistula and 
abscess formation, and extra intestinal manifestations, such as cutaneous 
ulcerations, uveitis, and arthropathy. The diagnosis of IBD is established by 
the clinical features and can be confirmed by endoscopic, radiologic, and 
histopathologic examination.5 Biopsy specimens from inflamed gut 
mucosa typically show inflammation, distorted crypt architecture, and 
crypt abscesses.
Treatment and prognosis
The choice of treatment of IBD depends on the location of the disease, 
its severity, and response to earlier therapy. Most clinicians initially treat 
patients with steroids, 5-aminosalicylic acid (5-ASA) agents, and 
antibiotics. Patients who are steroid dependent, and those with 
moderate to severe disease needing induction therapy with conventional 
corticosteroids, can be treated with azathioprine, mercaptopurine, and 
methotrexate. These so called immunomodulating drugs have been 
shown to be effective in inducing clinical remission, but their widespread 
use is limited by their toxicity. Infliximab and newer generation antibodies 
to tumor necrosis  factor (TNF)-α (certulizomab, adalimumab) have 
been shown efficacious as well, but are not able to maintain remission in 
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most patients. Thereby, the treatment of IBD remains challenging for 
treating physicians. 
In most patients with IBD, the course is chronic and intermittent. The 
disease responds less well to medical therapy with time and 
approximately 50-70% of the patients require surgical resection during 
the course of the disease. In the case of CD, surgery is accompanied by 
a high recurrence rate. On top of that, many patients have already had 
resections and are therefore at risk for developing short bowel 
syndrome. Consequently, there is an unmet need for more effective 
therapeutic strategies.
STEM CELL THERAPY 
A classical definition of a stem cell is a cell that has the capacity for self-
renewal and the ability to give rise to one or more types of 
differentiated progeny.6, 7 Self-renewal is defined as the ability of a cell to 
proliferate while it maintains its proliferation and differentiation 
potential. Stem cells are known to exist in different tissues but their 
frequency, exact function and identity are generally not well understood. 
Both in animal models and in patients, it appears that bone marrow 
derived cells play a role in the healing process following intestinal injury8 
and that these cells may contribute to regeneration of various mucosal 
components.9-11 The bone marrow contains at least two types of stem 
cells. One population consists of CD34 positive hematopoietic stem cells 
(HSC) committed to differentiate into all blood cell types, including the 
myeloid and lymphoid lineages. A second population of stem cells 
remains less well characterized. These non-hematopoietic stem cells are 
thought to support hematopoiesis and are variously known as 
mesenchymal stem cells, marrow stromal cells, and, more recently, 
mesenchymal stromal cells, all designated by the acronym MSC.12 
Hematopoietic stem cell transplantation
Although more than fifty years ago hematopoietic stem cell 
transplantation (HSCT) was introduced as a treatment for injury, it is 
now principally used as treatment for hematologic and lymphoid 
cancers.13 Evidence that HSCT is an effective treatment for autoimmune 
diseases comes from animal models14, 15 and case reports from HSCT 
recipients with coexistent autoimmune diseases.16 Ever since, autologous 
HSCT has been performed in more than 700 patients with autoimmune 
diseases,17 the most frequent indications being systemic sclerosis, 
multiple sclerosis, rheumatoid ar thr it is  and systemic lupus 
erythematosus.  
HSCT includes conditioning (immune ablation with high dose 
chemotherapy, total body irradiation and/or anti-lymphocyte antibodies), 
in which the bone marrow cells of the host are completely eliminated, 
followed by the infusion of either autologous or allogeneic stem cells. 
The HSCs are either directly harvested from the marrow or mobilized 
from bone marrow or blood before being harvested by apheresis. High 
dose immune ablation is an intensive treatment with risks of severe 
complications which on rare occasions have been fatal. In autologous 
transplantation, the individual’s own HSCs are harvested to be returned 
after conditioning. The graft is typically depleted of T-cells to avoid the 
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reinfusion of autoreactive T-cells. In allogeneic transplantation, the HSCs 
are harvested from a donor, usually a human leukocyte antigen (HLA) 
matched sibling. In addition to the complications associated with 
conditioning, allogeneic HSCT is  associated with a much higher 
transplant-related morbidity, due to graft-versus-host disease (GvHD), 
aplastic anemia, and hematological malignancies, and also a higher 
mortality rate (15-25% vs. 3-5%18) due to a considerable risk on GvHD. 
In view of the risks related to allogeneic transplantation most patients 
treated for autoimmune disease have received autologous transplants.
Hematopoietic stem cell transplantation in IBD patients for other indications
The possibility that autologous HSCT could be an effective treatment for 
IBD was suggested by the improvement of the clinical course of disease 
in patients with CD that received autologous transplantation for other 
indications.19-23 The first published abstract dates from 1993 and 
describes two year clinical remission in two patients with active IBD 
treated with autologous HSCT for breast cancer.19 Long term clinical 
remission after autologous HSCT was reported in a patient with clinical 
disease control of CD up to seven years following transplantation for 
non-Hodgkin lymphoma.21 Similar results were obtained in a 30-year-old 
patient with a ten year history of severe CD who developed Hodgkin’s 
disease and remained in complete treatment-free remission of both 
diseases three years after autologous HSCT24 and in an IBD patient who 
received HSCT for acute myeloid leukemia and had normal findings 
during ileo-colonoscopy at 1, 2, 3, and 5 years after transplantation.23
Similar to the first experience with autologous HSCT in IBD, the effect 
of allogeneic HSCT on IBD was initially described in patients treated for 
hematological malignancies. The first case report was published in 1998 
and described a 35-year-old male free of symptoms and signs of CD 
eight years post allogeneic marrow transplantation for acute leukemia.25 
A second report in the same year described six patients that underwent 
allogeneic transplantation for leukemia between 1962 and 1982.26 In this 
report, five out of six patients had active CD at time of transplantation. 
One patient died of septic complications 97 days after transplantation, 
the other five patients remained free of disease activity for more than 
one year post-transplantation. Only one out of these five patients 
relapsed during the follow up period of up to 15 years post-
transplantation. Interestingly, the only patient that developed a mixed 
donor-host hematopoietic chimerism following allogeneic HSCT 
continued to have active CD. In a retrospective study by Ditschkowski et 
al., ten out of eleven patients remained free of symptoms following 
allogeneic HSCT for hematological malignancies with a median follow-up 
time of 34 months.27 In another case report,28 a 41-year-old man with 
CD underwent al logeneic HSCT for lymphoma. Fol lowing 
transplantation, his bowel symptoms ceased and he was able to stop all 
immunosuppressive drugs. Eighteen months after transplantation 
colonoscopy showed no evidence of CD activity. Remission of UC 
following allogeneic HSCT has also been described.29, 30 Two patients, 
each with a long history of psoriasis  and UC, received an allogeneic 
HSCT for leukemia and remained in full remission four and twelve years 
after transplantation. 
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The coincidental treatment of IBD with both autologous and allogeneic 
HSCT increased the interest in the possibility that stem cell 
transplantation could be of value in IBD treatment. Autologous HSCs are 
infused only to shorten the post-HSCT neutropenic interval, in contrast 
with allogeneic HSCT in which the recipient’s  immune and hematologic 
system is replaced with that of a healthy donor without the genetic 
predisposition to IBD. In this light it has been proposed that the risk of 
disease recurrence may be higher after autologous HSCT.31
Early studies on HSCT specifically for Crohn’s disease 
The first reports of autologous HSCT specifically given for the treatment 
of CD were published in 2003 and concerned five patients with severe 
disease activity refractory to conventional treatment and treatment with 
anti-TNFα antibodies, who received autologous HSCT.32-34 No serious 
transplantation related complications were reported and all patients 
entered clinical remission. Some of the colonoscopies however, showed 
persistent mild inflammation up to one year post-transplantation. A 
larger phase I study on twelve patients with chronic active refractory CD 
also suggested that autologous HSCT can have a beneficial effect on CD 
activity. Besides fever, the autologous HSCT was well tolerated by the 
patients. Adverse effects included hematemesis from a Mallory-Weiss 
tear, a prolonged febrile course, clostridium difficile-induced diarrhea, and 
diarrhea after an upper respiratory tract infection. After fifteen months 
only one patient developed a recurrence of active CD. All others 
maintained in clinical and drug-free remission, but similar to the patients 
described in the reports above with persisting nonsymptomatic 
histologic and/or radiologic evidence of CD.35 In Chapter 2 of this 
thesis, the data on the clinical effect of HSCT in three patients with 
refractory CD can be found. 
Potential risks of hematopoietic stem cell transplantation
HSCT may be an effective treatment for CD but is also associated with 
a high morbidity and mortality rate.36 In 390 patients undergoing 
autologous HSCT for various autoimmune diseases, a mobilization 
associated mortality of 1.5% and an overall procedure related mortality 
of 9% were found.37 Early toxicity is related to direct organ damage 
either from the agents used or due to infection and bleeding during the 
10–12 days of bone marrow aplasia following the immunosuppressive 
conditioning period. Late toxicity relates to malignancy development due 
to the chemotherapy and/or radiation exposure. In addition, HSCT is 
associated with complications such as veno-occlusive disease of the liver 
and acute and chronic GvHD.38 Although HSCT seems a reasonably 
successful treatment for CD it is clear that, given the considerable 
mortality rate of HSCT for autoimmune diseases, this treatment should 
only be considered in selected cases of CD. HSCT could be considered 
as a last resort in patients with debilitating disease refractory to all 
immunosuppressive drugs, including the different anti-TNFα compounds 
now available for treatment, and in patients in which surgery is not a 
treatment option. 
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MSC Transplantation 
HSCT is thought to result in clinical remission in CD due to the 
combination of the immunosuppressive conditioning regimen and the 
replacement of the derailed lamina propria immune cells that maintain 
the disease. A novel emerging stem cell treatment may offer the benefit 
of immunosuppression without the need for condit ioning 
chemotherapy, even when given as allogeneic transplant.  
Mesenchymal stromal cells (MSC) reside in almost every type of 
connective tissue. Friedenstein and colleagues were the first to identify 
an adherent, fibroblast-like population of cells in the bone marrow.39 
Once isolated, these cells adhere to plastic, are capable of developing 
colony forming-units, and proliferate in vitro. In addition, MSCs are 
multipotent cells capable of differentiating into multiple lineages of the 
mesenchyme, including fat, bone, and cartilage tissue. MSCs consist of a 
heterogeneous population of cells and thus far no unique marker has 
been identified that allows reproducible isolation of precursors with 
predictable developmental potential. The isolation and characterization 
of these cells therefore still relies on their ability to adhere to plastic and 
their expansion potential. Isolated and expanded MSCs express CD73, 
CD90 and CD105 and are negative for hematopoietic stem cell markers 
(CD14, CD34, CD45), thereby distinguishing them from the 
hematopoietic stem cells.40 Furthermore, MSCs do not express major 
histocompability complex (MHC) class II or co-stimulatory molecules 
and are poor antigen presenting cells that do not elicit a proliferative 
response in allogeneic lymphocytes, which suggests that MSCs are of low 
immunogenecity. Although MSCs are present in virtually all tissues, our 
current knowledge is based on MSCs isolated from accessible tissues 
(e.g. bone marrow, adipose tissue, and umbilical cord blood).
Immunomodulatory capacities of MSCs
The immunomodulatory functions of MSCs were examined in vitro by 
coculturing them with purified subpopulations of immune cells. It has 
been shown that MSCs suppress several functions of naïve and memory 
T-cells,41-43 B-cells,44 and natural killer cells45, 46 as  well as the 
differentiation, maturation, and function of dendritic cells (DCs).47 
Furthermore, expanded MSCs alter cytokine secretion profiles of DCs, 
naïve and effector T-cells, and natural killer cells to induce a more anti-
inflammatory or tolerant phenotype.48 Even though cell-cell contact 
plays a role in the interaction between MSCs and other immune cells, 
immunosuppressive mechanisms of MSCs are mainly mediated through 
soluble factors. MSCs constitutively produce transforming growth 
factor-β1 (TGF-β1), hepatocyte growth factor (HGF), interleukin 
(IL)-10, prostaglandin E2 (PGE2), soluble HLA-G5, and IL-6 (Figure 1). The 
latter inhibits monocyte differentiation towards DCs and MSC-DC 
interaction directs DC maturation towards an anti-inflammatory or 
regulatory phenotype, thereby decreasing their stimulation capability on 
T-cells.47 Other factors, such as the enzyme indoleamine 2,3-dioxygenase 
(IDO), are released upon stimulation with inflammatory cytokines such 
as IFNγ and TNFα. IDO metabolizes tryptophan to kynurenin, which 
causes depletion of local tryptophan and accumulation of toxic 
breakdown products, thereby suppressing both CD4 and CD8 
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Figure 1. Schematic illustration of the immunomodulatory effects of MSCs on different cells of the immune system. After activation, MSCs secrete various factors, such as PGE2, IDO, and 
HLA-G.  These factors regulate the function and proliferation of NK cells, B-cells, and T-cells. Constitutively secreted IL-6 plays a role in the inhibition of alloantigen-induced generation and 
maturation of DCs and neutrophil activation. DC:  dendritic cell; HLA-G: human leukocyte antigen-G; IDO:  indoleamine 2,3-dioxygenase; IL: interleukin; IFN-γ: interferon-γ; MSC:  mesenchymal 
stromal cell; NO: nitric oxide; PGE2: prostaglandin E2; NK: natural killer ; Treg: regulatory T cell; TNF-α: tumor necrosis factor-α.
T-lymphocytes proliferation with mitogens and specific antigens.49, 50 
Although the involvement of the enzyme IDO has been consistently 
reported, IDO alone is not responsible for inhibition of T-cell 
proliferation, as IDO inhibitors were not able to restore proliferation of 
peripheral blood mononuclear cells (PBMCs). Moreover, MSCs lacking 
both IFNγ receptor 1 and IDO still exert immunomodulatory activity.51 
In mice, MSCs express very little IDO and is the induction of inducible 
nitric oxidase synthase (iNOS) essential in T-cell proliferation inhibition.52 
Available data on the interaction between MSCs and B-cells is 
controversial. MSCs have been shown to inhibit as well as stimulate B-
cell proliferation, depending on dose, source, and test system.53 For 
example, MSCs decrease proliferation and immunoglobulin secretion of 
B-cells in a 1:1 ratio,44 whereas in a lower concentration MSCs 
stimulates B-cell antibody secretion.54
Therapeutic applications of MSCs
Animal studies on models for tissue damage and autoimmune disease 
indicate that, similar to their immunosuppressive capacities in vitro, MSCs 
also display immunosuppressive capacities in vivo. For example, in a T-cell 
mediated experimental model of multiple sclerosis (MS) in mice, murine 
MSCs have been used to successfully treat experimental MS through the 
induction of peripheral T-cell tolerance.55 Systemically infused MSCs first 
show a wide-ranging distribution followed by homing to injured tissues,56 
including the gut,57 where they may participate in tissue repair. However, 
only a fraction of the systemically infused MSCs are traceable, and the 
fate of the remainder of the cells remains unknown. That intravenous 
infused MSCs entrapped as emboli are activated to secrete the anti-
inflammatory protein TSG-658 and that MSC derived molecules have 
anti-inflammatory properties,59 suggests that specific homing of MSCs to 
damaged tissues is not required for an effect.
In humans, the safety and feasibility of both local and systemic MSC 
administration has been studied in a variety of phase I and phase II trials. 
MSCs are low immunogenic and not restricted by MHC, therefore MSCs 
do not have to be human leukocyte antigen (HLA) matched to the 
recipient and can be infused without the need for conditioning 
chemotherapy, not even when given as allogeneic transplant. Both 
allogeneic and autologous MSCs are therefore currently under 
investigation. A great advantage of the allogeneic MSCs is their 
immediate availability. Furthermore, the age and fitness of the donor is 
controlled. MSC number and functionality decreases with age60, 61 and an 
ongoing discussion is whether MSCs might contribute to or if the MSCs 
are affected by the underlying disease. For instance, MSCs from patients 
with systemic lupus erythematosus yield low cell numbers and are 
difficult to grow in culture.62 Moreover, MSCs from patients with multiple 
myeloma are functionally defective and possibly contribute to the 
pathogenesis of the disease.63,64 Rationale for autologous application 
comes from data that MSCs may under certain conditions also be 
subject to immune rejection. In a  nonmyeloablated host, allogeneic 
MSCs are able to mount a T-cell memory response and consequently 
are eliminated.65 Comparable loss of immune privilege has been 
reported by others.66 
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The initial clinical trials were in patients with osteogenesis imperfecta67, 
followed by trials in which the immunosuppressive effects of the MSCs 
were used either to reduce the incidence of GvHD after allogeneic 
HSCT68 or as treatment of active disease, including GvHD of the gut.69 
Based on their ability to moderate T-cell response, MSCs are currently 
under evaluation in a range of (autoimmune) diseases (Table 1). 
Safety issues and concerns 
In the limited number of patients treated with MSCs in the last decade, 
few adverse events have been attributed to MSC administration. 
Although acute toxicity appears low, little is known about long-term 
unwanted side effects. Also, as mentioned before, safety concerns remain 
concerning immunogenecity and the dysfunction of MSCs due to the 
underlying disease. Moreover, potential hazards include the possibility of 
malignant transformation, ectopic tissue formation and the possible 
xenogenic transmission of disease and antibody formation when fetal 
bovine serum (FBS) is added to the culture medium. In fact, reports 
showed that extensively in vitro expanded stem cells may be prone to 
malignant transformation.70 It has been demonstrated by some groups 
that MSCs stimulate the growth of cancers and promote metastasis in 
rodents,71-73 although an increased risk of tumor formation has never 
been confirmed in humans.74 Moreover, two main works reporting 
transformation of human MSCs in culture were recently retracted as 
obtained data were based on tumor cell contaminated MSC cultures.75 
Although reassuring, safety issues remain important and it is  therefore 
essential to carefully characterize MSCs passaged in vitro to maximize 
safety for the recipient. Furthermore, patients should be thoroughly 
screened before MSC administration as the cells might enhance the 
growth of unknown cancer.
MSCs for IBD
Data from experimental colitis models
MSCs have been studied in both dextran sulfate sodium (DSS) and 
trinitrobenzene sulfuric acid (TNBS) colitis, in mice as well as in rats 
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Autoimmune diseases 
• Diabetes mellitus, type 1 and 2 
• Systemic sclerosis (SSc)   
• Systemic lupus erythematosus (SLE) 
• Primary Sjögren's syndrome (pSS)  
Orthopedics 
• Fractures 
• Arthrosis and arthritis
• Chondral and meniscal lesions  
• Articular cartilage defects  
Neurology 
• Amyotrophic lateral sclerosis (ALS)   
• Ischemic cerebral stroke 
• Multiple sclerosis (MS)  
• Parkinson's disease 
Cardiology
• Myocardial ischemia  
• Dilated cardiomyopathy  
• Chronic ischemic left ventricular 
dysfunction secondary to myocardial 
infarction
Table 1. Overview of indications for MSC therapy.  Registered trials were found using the International Clinical Trials Registry Platform (ICTRP), available on www.who.int/ictrp.
(Table 2). Different sources of MSCs have been used; i.e. bone marrow 
(bmMSCs), adipose tissue (atMSCs) and, though not commonly used, 
gingiva (gMSCs). Interestingly, MSCs obtained from both syngeneic and 
allogeneic sources have been applied and also human MSCs were 
studied in wild type mice (xenogenic). Systemic route of administration 
was either via the tail vein (rat) or intraperitoneally (i.p.) in mice. The 
latter prederred in mice as MSCs, due to their large size, frequently 
entrap in the pulmonary circulation which can cause acute death due to 
asphyxia.76 Local administration was also studied by injecting the MSCs 
into the colonic submucosa.77
The first two articles published in 2008 showed beneficial effects of the 
bmMSC in both DSS78 and TNBS77 colitis in rats. These data were 
further supported by two articles from the same group on atMSCs. In 
their first article, the authors showed that systemic infusion of MSCs 
obtained from adipose tissue ameliorated the clinical and histopathologic 
severity of TNBS colitis, abrogating body weight loss, diarrhea and 
inflammation, and increasing survival.79 A second paper supported these 
data by showing that systemic infusion of atMSCs protects against 
experimental DSS colitis and sepsis. The therapeutic effect was 
associated with down-regulation of the Th1-driven inflammatory 
responses.80 Zhang et al. nicely demonstrated that also MSCs from 
human gingiva, a tissue source easily accessible from the oral cavity, have 
similar immunomodulatory and anti-inflammatory proper ties as 
bmMSCs. In addition, they showed that a comparable therapeutic effect 
was mediated in the acute model of DSS colitis. This effect was achieved 
by the suppression of inflammatory infiltrates and inflammatory 
cytokines/mediators, by the increased infiltration of regulatory T-cells, and 
by the expression of anti-inflammatory cytokine IL-10 at the colonic 
sites.81 
Recent data suggest that resting MSCs do not have significant 
immunomodulatory activity, but that the immunosuppressive function of 
MSCs has to be elicited by interferon-gamma (IFN-γ).49, 50 In Chapter 5, 
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Hematology
• Myelodysplastic syndromes
• Graft-versus-host disease (GvHD)
Dermatology 
• Epidermolysis bullosa  
• Burn injury 
• Diabetic foot
  
Nephrology 
• Diabetic chronic kidney disease   
• Lupus nephritis 
• Chronic allograft nephropathy 
• Allograft rejection after renal 
transplantation
Other 
• Osteogenesis imperfecta
• Liver cirrhosis 
• Periodontitis 
• Inflammatory bowel disease (IBD) 
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Ref.   Species Colitis model Donor source Tissue source Cell number Route Timing Sarifice Outcome of MSC treatment
81 C57BL/6 7 days 3% DSS human bm and g 2x106 i.p.
one day after DSS 
initiation
day 10
Amelioration of colitis. Suppression of inflammatory infiltrates and inflammatory 
cytokines/mediators. Increased infiltration of regulatory T cells and the 
expression of anti-inflammatory cytokine IL-10 at the colonic sites.
80 C57Bl/6 acute colitis: 7 days 5% DSS at 105–5×106 i.p. day 2 day 5-14
C57Bl/6
chronic colitis: two cycles of 7 
days with 3% DSS, followed by a 
10-day period without DSS 
supplementation
at 1x106 i.p. day 7 each cycle day 10 or 26
91 male Lewis rats
DSS colitis with bone marrow 
hypoplasia: busulphan i.p. day 0, 
1% DSS day 5 - 10
SDTG (CAG-
EGFP) rat
bm 2x104/g tail vein day 7 day 10
Less severe colitis due to restoration of epithelial barrier integrity, no changes in 
cytokine expression
78 male Lewis rats 7 days 4% DSS syngeneic bm 5x106 tail vein day 0, 2, and 4 day 7
Reduction in bloody stools, weight loss, colon shortening, and microscopic 
injuries. Decrease in mRNA expression of TNF-alpha, IL-1beta, and COX-2 in the 
rectum of MSC treated rats. Suppression of VEGF, HGF, and b-FGF. Green-
fluorescent-labeled MSCs in lamina propria of inflamed regions.
Ref.   Species Colitis model Donor source Tissue source Cell number Route Timing Sarifice Outcome of MSC treatment
79 BALB/c 
3 or 5 mg TNBS in 50%EtOH 
intrarectally
human, 
allogeneic and 
syngeneic
at 105–106 cells i.p.
12 hours after TNBS 
installation
day 3 and 10
BALB/c 
4 or 5 mg TNBS in 50%EtOH 
intrarectally
human at 1x106 i.p.
2 consecutive days 
starting day 6
day 14
BALB/c  1.5 mg TNBS day 0 and 9 human at 1x106 i.p.
12 hours after the 
first infusion of TNBS
day 14
77
male Sprague-
Dawley rats
0.15 M TNBS in 35% EtOH syngeneic bm 1x107
injected into the 
colonic 
submucosa 
immediately after the 
TNBS-induced colon 
injury
day 6
The engrafted MSCs survived and accelerated healing of TNBS-induced colitis. 
After the implantation, the MSCs became potential sources of VEGF and       
TGF-β1, angiogenic and immunomodulating factors, in colon tissues.
Amelioration of the clinical and histopathological severity of colitis. Less weight 
loss, diarrhoea and inflammation, and increase in survival. Downregulation of the 
Th1-driven inflammatory responses.
Protection against colitis, reduction in histopathologic signs and infiltration of 
macrophages, lymphocytes, and neutrophils. Reduced levels of inflammatory 
cytokines (TNF-α, IFN-γ, IL-6, IL-1β, and IL-12) and chemokines. Abrogation of 
established colitis. Increased levels of the anti-inflammatory/regulatory cytokine IL-
10. Reduction of disease recurrence.
human, 
allogeneic and 
syngeneic
Table 2. Published studies with mesenchymal stromal  cells in experimental models of colitis. A literature search in Pubmed was performed using the following keywords, alone or in combina-
tion: ‘mesenchymal stem cell’, ‘mesenchymal stromal cell’, ‘colitis’, ‘crohn’s disease’ and ‘inflammatory bowel disease’.
the effects of IFN-γ prestimulation of MSCs (IMSCs) was assessed in 
vitro and in animal models of colitis, demonstrating an enhanced 
therapeutic activity of MSCs after IFN-γ exposure.
Clinical trials in patients with Crohn’s disease
Currently, multiple trials on MSCs for the treatment of CD are 
registered in the public registries for clinical trials (Table 3). The indication 
is either active luminal disease, for which MSCs are injected 
intravenously, or fistulizing disease, for which MSCs are injected locally in 
fistula tracts. Cells are isolated from bone marrow or from adipose tissue 
and from either the patient itself (autologous) or from a healthy donor 
(allogeneic). At least three companies are currently investigating the 
application of MSCs in Crohn’s disease, i.e. Anterogen (Korea), Cellerix 
(Spain) and Osiris (USA). 
Completed trials
Safety of local application of atMSCs in the treatment of fistulizing CD 
was demonstrated in a phase I clinical trial in which in total nine fistulas 
in four patients were inoculated with autologous atMSCs. Although the 
results are preliminary and follow-up is short, they are interesting as after 
8 weeks 75 percent of these fistulas were considered healed and no 
adverse effects were observed in any of these patients.82 This phase I 
study was followed by a multicenter, randomized, controlled trial 
sponsored by Cellerix to evaluate the efficacy and safety of atMSCs. 
Forty-nine patients with complex perianal fistula from cryptoglandular 
disease (n=35) or CD (n=14) were included. Patients received fibrin 
glue or 20 million cells plus fibrin glue intralesionally. Fistula healing was 
evaluated at 8 weeks. If not healed, a second dose of fibrin glue or 40 
million cells plus fibrin glue was administered, with healing evaluated 8 
weeks later. Healing was defined as absence of drainage and complete 
reepithelization of the external openings. The proportion of patients 
whose fistulas were healed was significantly higher with atMSCs than 
with fibrin glue alone in the CD as well as the non CD patients.83 Osiris 
Therapeutics uses Prochymal™, MSCs obtained from the bone marrow 
of healthy adult volunteer donors. Although a significant decrease of the 
Crohn’s disease Activity Index (CDAI) score was observed in the phase I 
trial, 84 the company recently terminated a phase III trial because of a 
high placebo response rate. Unfortunately, the results have not yet been 
published in peer reviewed journals. In Chapter 3 the feasibility and 
safety of the intravenous application of autologous MSCs obtained from 
the bone marrow (bmMSC) of CD patients, was assessed in a phase I 
trial.85 
Ongoing studies
The Royal Perth Hospital (Australia) has just launched a multicenter 
phase II trial in 20 patients to evaluate the safety and efficacy of weekly 
intravenous infusion for 4 weeks with allogeneic bmMSCs. The University 
Hospital La Paz in Madrid is performing a phase I/IIa trial on allogeneic 
atMSCs in the local treatment of recto-vaginal fistula in CD. The Leiden 
University Medical Center (LUMC) is currently investigating the safety 
and preliminary efficacy of allogeneic bmMSCs in the induction of 
response for active fistulizing CD in a dose escalation study.
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Main trial ID Title Indication Cell type and source Dose Delivery route Time of delivery Primary endpoint Phase and design
Patient 
number
Site/company
Recruiting
NCT01011244
A Phase II Clinical Study of ADIPOPLUS (Autologous Cultured Adipose-
derived Stem Cell) for the Treatment of Crohn's Fistula to Evaluate 
Safety and Efficacy
Fistula autologous/at in fistula site
1) Efficacy: more than half closure of fistula (week 8) 2)Safety: 
Clinically measured abnormality of laboratory tests and adverse 
events
Phase II, uncontrolled Anterogen Co., Ltd.
NCT01090817
A Multicentre Australian Phase 2 Study to Evaluate Safety and Efficacy 
of Mesenchymal Stromal Cells for Treating Biologic Refractory Crohn's 
Disease
Luminal allogeneic/bm
2x106/kg recipient 
weight
intravenous weekly for 4 weeks
Clinical response to MSC: Reduction of Crohn's disease Activity 
score by 100 points or more at six weeks post start of therapy
Phase II, non-
randomized, 
historical controls
20 Royal Perth Hospital
NCT00999115
Clinical Trial in Phase I-IIa to Study the Feasibility and Security of the 
Allogenic Use of Adipose-derived Stem Cells for the Local Treatment of 
Recto-vaginal Fistula in Crohn´s Disease
Recto-vaginal fistula allogeneic/at 20x106 cells intralesional injection
at baseline with a possible second 
administration of 40x106
Percentage of subjects in whom the external openings of the 
treated rectovaginal fistula have closed (12 weeks)
Phase I-IIa 10
Biomedica del Hospital 
Universitario la Paz
NCT01020825
A Prospective Study for the Assessment of the Long-term Safety and 
Efficacy of Cx401 in Patients Taking Part in the FATT-1 Trial
Perianal fistula autologous/at 20 and 40x106 intralesional injection
Cumulative incidence of adverse events (clinical or laboratory) 
attributed to the study therapy in the preceding FATT-1 
randomized trial (CX401 or fibrin glue) (6 months)
Prospective, 
observational
150 Cellerix
NCT01144962
Dose-escalating Therapeutic Study of Allogeneic Bone Marrow Derived 
Mesenchymal Stem Cells for the Treatment of Fistulas in Patients With 
Refractory Perianal Crohn's Disease
Perianal fistula allogeneic/bm
10, 30, 90x106 or 
placebo
intralesional injection baseline
 1) The number of adverse and serious adverse events and 2) a 
reduction in the number of draining fistulas (12 weeks)
Phase I-II, dose 
escalation
21
Leiden University Medical 
Center
Active, not recruiting
NCT00482092
A Phase III, Multicenter, Placebo-Controlled, Randomized, Double-Blind 
Study to Evaluate the Safety and Efficacy of PROCHYMAL[tm] (ex Vivo 
Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion 
for the Induction of Remission in Subjects Experiencing Treatment-
Refractory Moderate-to-Severe Crohn's Disease
Luminal allogeneic/bm
600 or 1200 x106 or 
placebo
intravenous over 4 infusions in 2 weeks Disease remission (CDAI at or below 150) (28 days)
Phase III, multicenter, 
placebo-controlled, 
randomized, double-
blind 
270 Osiris Therapeutics
Completed
NCT00543374
A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind 
Durability and Retreatment Study to Evaluate the Safety and Efficacy of 
PROCHYMAL™ (ex Vivo Cultured Adult Human Mesenchymal Stem 
Cells) Intravenous Infusion for the Maintenance and Re-induction of 
Clinical Benefit and Remission in Subjects Experiencing Treatment-
refractory Moderate-to-severe Crohn's Disease
Luminal allogeneic/bm NA NA NA
1) Duration of clinical benefit 2) Re-induction of clinical benefit 
(6 months)
Observational, 
double blind, 
randomized, placebo-
controlled
Osiris Therapeutics
NTR1360
Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of 
Refractory Crohn's Diseas
Luminal autologous/bm
2x106/kg body 
weight
intravenous 2 infusions, one week apart
1) Safety: rate of (serious) adverse events in the study 
population 2) Feasibility: determination of the number of 
expanded MSCs in relation to the amount of bone marrow 
collected, number of passages required and time to reach study 
target doses (week 6) 
Phase I, open label 10
Leiden University Medical 
Center
NCT00294112
A Phase II, Open-Label, Randomized Study to Evaluate the Safety and 
Efficacy of PROCHYMAL™ IBD (ex Vivo Cultured Adult Human 
Mesenchymal Stem Cells) Intravenous Infusion for the Treatment of 
Subjects Experiencing Moderate-to-Severe Crohn's Disease That is 
Refractory to Steroids and Immune Suppressants
Luminal allogeneic/bm
2 or 8x106/kg body 
weight
intravenous 2 infusions, one week apart Crohn's disease activity index (28 days)
Phase I, open label, 
randomized
10 Osiris Therapeutics
NCT00992485
A Phase I Dose Escalation Clinical Study of ADIPOPLUS (Autologous 
Cultured Adipose-derived Stem Cell) for the Treatment of Crohn's 
Fistula to Evaluate Safety and Efficacy
Fistula autologous/at Escalating doses in fistula site
1) Efficacy: closure of fistula (week 8) 2) Safety: Clinically 
measured abnormality of laboratory tests and adverse events
Phase I, dose 
escalation
9 Anterogen Co., Ltd.
NCT01144962
Dose-escalating Therapeutic Study of Allogeneic Bone Marrow Derived 
Mesenchymal Stem Cells for the Treatment of Fistulas in Patients With 
Refractory Perianal Crohn's Disease
Perianal fistula allogeneic/bm
10, 30, 90x106 or 
placebo
intralesional injection baseline
 1) The number of adverse and serious adverse events and 2) a 
reduction in the number of draining fistulas (12 weeks)
Phase I-II, dose 
escalation
21
Leiden University Medical 
Center
Table 3. Registered clinical trials on mesenchymal stromal cells in Crohn’s disease. Both recruiting and completed trials are listed (sources: clinicaltrials.gov and trialregister.nl).
Safety issues and concerns
In the case of autologous MSCs, an ongoing discussion is whether MSCs 
are affected by or may contribute to the underlying disease. For 
instance, MSCs from patients with systemic lupus erythematosus are 
difficult to expand in culture and yield low cell numbers62 and those 
from patients with multiple myeloma have been shown to be impaired 
and possibly contribute to the pathogenesis of the disease.86 Chapter 3 
therefore evaluates MSCs obtained from refractory CD patients, 
focusing on growth potential, yield, and functional properties. 
Previous studies showed that immunosuppressive drugs can be harmful 
to hematopoietic stem cells or endothelial progenitor cell proliferation, 
thereby affecting their functional capacities.87-90 We hypothesized that 
likewise, immunosuppressive agents might have an effect on MSC 
function and could, therefore, change the outcome of MSC therapy and 
affect safety. Chapter 4 investigates the interaction between MSCs and 
immunosuppressive drugs frequently used in the treatment of IBD.
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ABSTRACT
Although new therapeutic strategies have been developed to control 
Crohn`s disease, medical treatment for refractory cases is not able to 
prevent extensive and/or repeated surgery. Recently, several cases have 
been reported of successful remission induction in Crohn’s disease (CD) 
patients by means of hematopoietic stem cell transplantation (HSCT). 
Here we report our long-term (4 to 6 years) outcome in three patients.
Patients 
Three patients (two male, one female) with active severe CD were 
planned to undergo autologous HSCT. All patients were intolerant or 
refractory to conventional therapies, including anti-TNFα antibodies. 
Patients either refused surgery or surgery was considered not to be a 
feasible alternative due to the extensive disease involvement of the small 
intestine.
Methods 
Peripheral blood stem cells were mobilized using a single infusion of 
cyclophosphamide 4g/m2, followed on day 4 by subcutaneous injections 
with granulocyte colony-stimulating factor (G-CSF) 5μg/kg twice daily until 
leukapheresis. CD34+ cells were isolated after leukapheresis by magnetic 
cell sorting. In two of the patients a second round of stem cell mobilization
using G-CSF only was required either because of low yield or because of 
insufficient recovery after CD34 selection. Prior to transplantation, immune 
ablation was achieved using cyclophosphamide 50 mg/kg/day (4 days), 
antithymocyte globulin 30 mg/kg/day (3 days) and prednisolone 500 mg (3 
days). Endoscopy, barium small bowel enteroclysis and MRI enterography 
were performed.
Results 
All three patients successfully completed stem cell mobilization and two of 
them subsequently underwent conditioning and autologous HSCT with 
CD34+ cell selection. Treatment was well tolerated, with acceptable 
toxicity. Now, 5 and 6 years post-transplantation, these patients are in 
remission under treatment. The third patient went into remission after 
mobilization and therefore she decided not to undergo conditioning and 
HSCT transplantation. After a successful pregnancy she relapsed two years 
later. Since then, she suffers from refractory CD for which we are now 
reconsidering conditioning and transplantation.
Conclusion 
Autologous HSCT appears to be safe and can be an alternative strategy 
for CD patients with severe and therapy resistant disease. 
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INTRODUCTION
Crohn’s disease is an inflammatory disorder of potentially any part of the 
gastrointestinal tract, leading to various intestinal but also extra-intestinal 
symptoms. It is thought that dysregulation of the normally controlled 
immune response to commensal bacteria in genetically susceptible patients 
drives the disease.1 Although medical therapy of inflammatory bowel 
disease (IBD) has improved due to an extensive repertoire of 
immunosuppressive drugs and the introduction of anti-tumor necrosis 
factor-α (TNFα) compounds, the clinical course of the disease cannot be 
adequately controlled in a substantial group of patients. These patients may 
not respond or may become refractory to their medication, or they may 
develop treatment limiting toxicities.2 The course of the disease is chronic 
and intermittent and the disease responds less well to medical therapy 
over time. Half of the patients require surgical resection during the course 
of the disease.3 Unfortunately, surgery is accompanied by a high 
recurrence rate and many patients are at risk to develop short bowel 
syndrome. Therefore, there is an unmet need for more effective 
therapeutic strategies.
Evidence that hematopoietic stem cell transplantation (HSCT) would be 
an effective treatment for autoimmune diseases firstly came from several 
animal models4, 5 and from incidental case reports on HSCT recipients 
with coexistent autoimmune disease.6 Already more than 15 years ago a 
case report on the positive effect of HSCT on active IBD was published, 
followed by many others showing improvement of the clinical course of 
disease after HSCT indicated for other (malignant) diseases.7 In the last 
couple of years, several cases have been reported of successful remission 
induction of patients with (therapy refractory) CD by means of an 
autologous HSCT. The most  extensive experience on autologous HSCT 
applied specifically for CD has been reported by Oyama and colleagues.8, 9 
All twelve treated patients went into remission with a Crohn’s disease 
activity index (CDAI) score of <150. There was no inpatient mortality and 
neutropenic fever was the most important complication. Recently 
published long-term follow-up data showed a clinical relapse-free survival 
of 63% at 3 years and 36% at 5 years. The percentage of patients in 
remission (CDAI < 150), steroid free, or medication free at any post 
transplant evaluation interval over 5 years post transplant was respectively 
70%, 80% and 60%.8 
Supported by these reports we have mobilized stem cells in three patients 
with severe refractory CD, for whom surgery was not a feasible option 
due to extensive disease activity, and performed autologous HSCT 
in two of these patients. Here, we report on the follow-up period 
of four to six years. 
MATERIAL AND METHODS 
Patient selection
Three patients with severe refractory CD were selected for an autologous 
HSCT procedure. The considerations for selection included longstanding 
refractory disease and exhaustion of the full range of therapeutic strategies 
such as anti-TNFα antibodies. In addition, surgery was unattractive 
because of unwillingness of the patients and the likelihood of either 
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developing short bowel syndrome (patient 1) or a definite ileostomy 
(patients 2 and 3). All cases were reviewed prior to selection by an 
independent gastroenterologist. The protocol was approved by the Medical 
Ethics Committee of the Academic Medical Center (AMC), Amsterdam, 
the Netherlands. All patients gave written informed consent.
HSCT protocol
Mobilization: Prior to cyclophosphamide treatment, semen was 
cryopreserved of the male patients. The female patient was offered 
treatment with the luteinizing hormone-releasing hormone analague 
gosereline, in an attempt to prevent chemotherapy-induced gonadal 
toxicity and premature ovarian failure.10 Peripheral blood stem cells were 
mobilized using a regimen consisting of a single intravenous dose of 
cyclophosphamide 4g/m2 followed on day 4 by granulocyte colony-
stimulating factor (G-CSF) twice daily, 5μg/kg/day. Hyperhydration and 
mesna prophylaxis were given in order to prevent hemorrhagic cystitis. 
Partial bowel decontamination was obtained using oral ciprofloxacin and 
fluconazol. In addition, all patients received antibiotic prophylaxis consisting 
of clarithromycin. Peripheral blood stem cells (target >8 x106 CD34+ 
cells/kg body weight) were collected by large volume leukapheresis using a 
COBE Spectra leukapheresis machine (COBE BCT, Lakewood CO) as 
soon as the white blood cell count was >2x109/l and CD34+ cells were 
detectable in the peripheral blood. CD34+ cells were isolated within 48 
hours after leukapheresis by magnetic cell sorting (CliniMACS CD34 
selection procedure, Miltenyi Biotec, Bergisch Gladbach, Germany) 
according to the manufacturer’s instructions. The CD34+ cells  were 
cryopreserved in dimethyl sulfoxide (DMSO) and stored in the vapor 
phase of liquid nitrogen until transplantation. Conditioning: Prior to 
t r ansp l an ta t ion , immune ab l a t ion was ach ieved us i ng an 
immunosuppressive conditioning regimen consisting of cyclophosphamide 
50 mg/kg/day intravenously and equine antithymocyte globulin 
(Lymphoglobulin, hATG, Genzyme Corporation, Boston, MA, USA) at a 
dosage of 30 mg/kg/day (on days -4, -3, -2). Premedication with 
methylprednisolone at a dose of 500 mg/day was administered 
intravenously for three consecutive days from day 4 and prednisolone was 
subsequently tapered over a period of 14 days. Hematopoietic stem cells 
were thawed and infused intravenously on day 0. Transplantation: Patients 
were hospitalized and nursed in clean rooms. Following transplantation, 
partial bowel decontamination was obtained using oral ciprofloxacin and 
fluconazol, and patients received antibiotic prophylaxis consisting of 
metronidazol and intravenous penicillin starting on day 5 until recovery of 
neutropenia. Supportive care were given when indicated. The hemoglobin 
level was maintained above 9.7 g/dl and platelet counts above 10 x109/l. All 
blood products, excluding the peripheral blood progenitor cells, were 
irradiated prior to infusion. 
Evaluation of clinical response
Clinical assessment during HSCT and follow-up included medical history, 
physical examination and standard biochemical tests (including CRP). 
Endoscopy and both barium small bowel enteroclysis and MRI 
enterography were performed at baseline and after 3 and 6 months where 
indicated. 
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RESULTS
HSCT was offered to 3 patients (2 male, 1 female) with a median age of 
28 (range 27-51). Patients were resistant or intolerant to conventional 
medication, including anti-TNFα therapy. All drugs, including steroids, were 
tapered after the mobilization procedure. Patient disease characteristics 
are described in table 1. 
Safety and efficacy of stem cell mobilization 
In general, the stem cell mobilization procedure with cyclophosphamide 
and G-CSF was safe. Besides minor expected side-effects such as nausea 
which were successfully managed, there were two major complications: in 
patient 1 a transient deterioration of kidney function was observed due to 
decreased oral intake because of nausea, which responded rapidly to 
intravenous fluids. Patient 2 had an episode of culture-negative neutropenic 
fever, which was empirically treated with broad-spectrum antibiotics. The 
blood cultures remained negative and the fever resolved promptly. 
In patient 1, a sufficient number of stem cells was harvested (28.9x106 
CD34+ cells/kg) in only one leukapheresis procedure. Despite a rather 
low recovery after CD34+ selection of 27%, a large enough amount of 
stem cells for reinfusion (7.87x106/kg) with a purity of 97% was obtained. 
In patient 2 and 3 however, a second stem cell mobilization procedure was 
required. In patient 2 the initial yield was sufficient (10.6x106 CD34+ cells/
kg), but due to low recovery the yield after CD34 selection was borderline 
(2.5x106 CD34+ cells/kg). Therefore, a second mobilization 
procedure using only G-CSF 5 μg/kg twice daily for 5 days was performed 
two months later. The second mobilization yielded a total 2.1x106 CD34+ 
cells/kg, with 50% recovery after CD34 selection and a purity of 94%. In 
patient 3 the first attempt at stem cell mobilization with cyclophosphamide 
priming failed with a total yield after two leukapheresis procedures of 
1.85x106 CD34+ cells/kg. Because of the low yield, CD34 selection was 
not performed. A second attempt at stem cell mobilization was done 
three months later using only G-CSF 5 μg/kg twice daily for 5 days. This 
resulted after two days in a yield of 5.84x106 CD34+ cells/kg, with a 
recovery of 53% and a purity of 89.7%. A third leukapheresis yielded 
1.7x106 CD34+ cells/kg with a recovery of 66.5% and a purity of 79.7% 
after CD34 selection.
During the stem cell mobilization phase patient 1 required one transfusion 
of red blood cells (RBC) (3 units), patient 2 required two transfusions (in 
total 7 units of RBC) and patient 3 received one platelet transfusion 
(pooled platelets from five donors).
Safety of hematopoietic stem cell pretreatment and transfusion
During  HSCT conditioning, patient 1 developed an allergic reaction (fever 
and hypotension) to antithymocyte globulin (ATG), that resolved with fluid 
challenge. Patient 2 had a quick and transient deterioration of kidney 
function due to hypotension after the first dose of ATG. In patient 1 and 2 
respectively, a total of 5.9x106 and 3.5x106  CD34+ cells/kg were 
reinfused. The posttransplantation course was uneventful with an episode 
of rotavirus-associated diarrhea in both patients, clostridium difficile-
28    Chapter two
Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn`s disease    29
Patient 1 2 3
Basal demographic and clinical characteristics
Sex male male female
Year of birth 1953 1978 1978
Diagnosis 2003 2004 1999
Disease extension stomach, duodenum, jejunum, ileum colon including rectum colon including rectum
Montreal
Disease pattern stricturing and penetrating penetrating penetrating
Extraintestinal disease manifestations no stomatitis artralgia
Risk factors none previous smoker previous smoker 
Previous treatments
   5-asa yes yes yes, intolerant
   Corticosteroids yes yes yes, intolerant
   Antibiotics yes yes yes
   Azathioprine yes yes yes, leucopenia
   Infliximab yes yes yes
   Methotrexate yes yes yes
   visilizumab no yes yes
   Adalimumab no no no
   Surgery no no no
HSCT
   Age at HSCT 51 27 28
   Year of HSCT 2004 2005 2006
Crohn’s disease medication
   At time of mobilization prednisone 15 mg prednisone 30 mg none
   At time of transplantation prednisone 60 mg prednisone 40 mg not applicable
Table 1. Basal demographic, medical history. and clinical characteristics at time of  HSCT.
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associated diarrhea and an episode of fever caused by a central venous 
catheter-associated coagulase-negative staphylococci (CNS) bacteremia in 
patient 2. Recovery of neutrophils to >0.5x109/l was reached at day 12 
and 14 in patient 1 and 2, and recovery of platelets >50x109/l was seen at 
day 14 and 9 respectively. Patient 1 required transfusion with six units of 
RBC and 3 platelet transfusions; patient 2 required six units of RBC and 1 
platelet pool. Both patients discontinued their immunosuppressive 
therapies post HSCT and regained normal appetite and oral intake. 
Clinical evaluation of HSCT treatment and follow-up
At a median follow-up of 62 (range 58-75) months all patients are alive. 
The two patients (Patient 1 and 2) who underwent the complete HSCT 
protocol are in clinical remission under immunosuppressive therapy. The 
patient (patient 3) who underwent stem cell mobilization only, remained in 
clinical remission and off of all immunosuppressive drugs for more than 
two years. A detailed description of the follow-up on these patients is 
described below:
Patient 1: 
Patient 1 is a 51-year-old male with diagnosed CD of the stomach and 
almost the entire small bowel dependent on parenteral nutrition. This 
patient was offered autologous HSCT because he was unresponsive to 
immunosuppressive drugs (steroids in combination with azathioprine/
methotrexate) and biologic therapy (infliximab). Surgery would have put 
him at great risk of developing a short bowel syndrome as the whole small 
intestine was affected by the disease. After mobilization, an initial clinical 
response was observed. However, the patient experienced a clinical and 
endoscopic relapse within ten weeks. After immune ablation a total of 
5.9x106/kg CD34+ cells/kg was reinfused and the patient could be 
discharged on day 15 after HSCT. In week 8 following transplantation, the 
patient was clinically in a partial remission, gaining weight (4 kg) without 
need for supplementary parenteral nutrition. 
Follow-up: At 8 weeks clear improvement of the inflammatory lesions was 
observed endoscopically (Figure 1A). Also, barium enteroclysis (Figure 1B) 
and MRI enterography (Figure 1C) showed regression of small bowel 
stenosis. A sharp drop in CRP levels was seen after the mobilization 
phase, which further decreased during follow-up (Figure 1D). Two months 
after transplant the patient unexpectedly developed leukopenia (1.6x109/
l), which resolved spontaneously within 2 months. Six months post-
transplant the patient developed abdominal pain and gastric ulcers were 
detected during gastroscopy. Biopsies did not reveal Helicobacter pylori, 
cytomegalovirus, Epstein–Barr virus or other infectious agents and the 
ulcers had vanished two months later. MRI performed at 10 weeks showed 
no improvement compared to the baseline MRI, which showed bowel wall 
thickening, stenosis and inflammation of the horizontal part of the 
duodenum and jejunum. At the MRI performed at 6 months persistence of 
stenotic segments of the duodenum was seen. However, inflammatory 
activity evidently decreased and the stenosis in the jejunum disappeared 
(Figure 1D). As expected, residual strictures in the duodenum persisted 
which were dilated three (1x), twelve (3x), and 36 (1x) months after 
transplantation. 
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Figure 1. A Endoscopic changes after HSCT of patient 1. Duodenal  ulcerations at the week 0 endoscopy (upper panels)  and healing of duodenal  mucosa at week 8 after HSCT (lower 
panels). B Barium small bowel enteroclysis of patient 1 at baseline and 8 weeks after HSCT shows regression of small bowel  stenosis. C MRI enterography at week 10 and week 24 post 
HSCT. Coronal fat saturated T1-weighted sequence after intravenous contrast administration shows a reduction in the extension of a stenosis in the jenunum (arrow). D CRP levels during the 
mobilization phase and indicated number of weeks post HSCT.
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Twelve months post-transplantation azathioprine was started (150 mg/
day) and switched to certoluzimab two years post-transplantation because 
of leukopenia and thrombocytopenia. Repeat gastroscopy with enteral 
balloon dilatation of his proximal strictures was last performed in 2006. In 
2007, he was admitted for unexplained ascites. Extensive work-up 
excluded common causes such as primary sclerosing cholangitis, portal 
hypertension, and hepatitis. The ascites resolved spontaneously without 
continued use of diuretics. 
At present, the patient is  doing relatively well. His weight has improved 
over the years and he now only sporadically vomits following meals. 
During his six years of follow up he did not have a luminal relapse of his 
CD and certolizumab treatment will be continued.
Patient 2
The next patient is  a 27-year-old male patient with a short but 
complicated history of refractory CD of the colon unresponsive to 
immunosuppresive drugs (azathioprine and methotrexate), failing on 
infliximab and experimental anti-CD3 (visilizumab) therapy. In July of 2005 
he underwent stem cell mobilization followed by HSCT in October of the 
same year. After HSCT, the stool frequency dropped from bloody and 
watery >10/day to semisolid without blood 6-7 times daily before hospital 
discharge. Dramatic improvement of the colonic mucosa was observed 
during colonoscopy at 10 weeks. The ulcerated areas had regained 
epithelium and no active inflammation was seen. 
Follow-up: Six months after HSCT, 6-MP (mercaptopurine 100 mg) was 
started combined with infliximab. After having experienced no clinical 
complaints and having a high quality of life for five years, he relapsed with a 
mildly active distal colitis in the beginning of 2010. He was switched from 
infliximab to adalimumab, continuing 6-MP, and three months following his 
change of therapy he was again in complete clinical remission, with 
normalized CRP levels.
Patient 3
The third case is a 28-year-old female patient with a similar history. She has 
a completely refractory (included failure of anti-TNFα therapy) CD of her 
colon complicated by arthritis and perianal abscesses, needing multiple 
hospital admissions yearly. Patient refused colectomy and was therefore 
planned to undergo HSCT. In this patient, complete clinical remission was 
achieved after the stem cell mobilization procedure. For this reason the 
stem cell transplantation itself was deferred. 
Follow-up: The patient remained in complete clinical and endoscopic 
remission without any medication for two years and had an uncomplicated 
pregnancy 1.5 years after mobilization. In 2008, she relapsed with a severe 
active Crohn’s colitis for which she was treated with infliximab and 
methotrexate. After three infusions she experienced an allergic response 
to infliximab and, despite proper anti-allergic medication, a loss of 
response. Transplantation of the mobilized and stored CD34+ cells was 
proposed to the patient, which she declined because of cyclophosphamide 
associated toxicity. Consequently, she was included in a phase I trial on the 
safety and feasibility of autologous mesenchymal stromal cell  infusion in 
refractory CD, for which conditioning is not needed (see Chapter 3 of this 
thesis).11 No response was achieved and currently she experiences 
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persistent but tolerable activity with weekly adalimumab treatment in 
combination with steroids. As no medical therapeutic options are left we 
are now reconsidering conditioning and transplantation.
DISCUSSION 
Our first experience of autologous HSCT for CD, employing similar 
protocols for mobilization, conditioning and supportive care as used in 
other published articles on HSCT for CD12 is encouraging, as our patients 
have, since the onset of their disease, never been in remission for as long 
as after HSCT. The effect of HSCT was only partially successful in resolving 
Crohn’s lesions at endoscopy. There was no transplant-related mortality 
and adverse effects were manageable. In one patient, an unexplained 
prolonged leukopenia following transplantation was observed which 
occurred two months after initial neutrophil recovery and which was not 
associated with infectious complications. 
We did observe some difficulties with stem cell mobilization and CD34+ 
selection. In two of the patients, the initial procedure yielded an insufficient 
amount of CD34+ cells either before or after selection. This may in part 
have been due to the prior use of methotrexate in both patients, 
combined with thalidomide in one of the patients, even though this 
medication was stopped two months before the cyclophosphamide 
mobilization treatment. A subsequent second attempt at stem cell 
mobilization using G-CSF only was successful, although two leukapheresis 
procedures were required for both patients. The recovery of CD34+ cells 
after selection using the CliniMACS selection procedure was rather low 
(median 48.5%, range 23-66.5%). Whether this is related to the underlying 
disease is unknown, but similar low recovery rates were not reported in 
the series published by Oyama et al.9
Recently, safety and efficacy of autologous HSCT with unselected 
peripheral blood stem cells was demonstrated in four previously 
refractory CD patients.13 In our study, peripheral blood cells were used 
after CD34+ cell selection in order to deplete activated T-cells to reduce 
the likelihood of relapse related to the reinfusion of autoreactive T-cells.14 
The last case is a good example of the role of the immunosuppressive 
effects of the stem cell mobilization regime which includes a high dose of 
cyclophosphamide. In 390 patients undergoing autologous HSCT for 
various autoimmune diseases a mobilization associated mortality of 1.5% 
and an overall procedure related mortality of 9% were found.15 To 
evaluate the efficacy of HSC mobilization followed by high dose immune 
ablation and autologous stem cell transplantation versus HSC mobilization 
only, a multicenter, prospective, randomized phase III study has been 
initiated by the European Crohn's and Colitis Organisation (ECCO) in 
collaboration with the European Group for Blood and Marrow 
Transplantation (EBMT). 
Not only autologous but also allogeneic HSCT has been shown to 
maintain remission in CD patients.16 Theoretically, due to the additional 
graft versus autoimmunity effect in allogeneic HSCT this approach could 
give a longer lasting effect than autologous HSCT in the treatment of CD, 
even after withdrawal of prophylactic immunosuppression.17 Allogeneic 
HSCT is, however, associated with graft-versus-host disease and has a 
considerably higher morbidity and mortality than autologous HSCT.18 
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Therefore, allogeneic HSCT at this  point does not seem to be a viable 
option for a nonmalignant disease with very low mortality rates.
In conclusion, autologous HSCT is a relatively well tolerated and safe 
procedure. Given the considerable mortality rate of HSCT for 
autoimmune diseases, this treatment should only be considered in highly 
selected patients with severe and therapy resistant disease, or for patients 
for whom surgery is  not a treatment option. Larger clinical trials  are and 
should be conducted as more information is warranted.
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ABSTRACT
Background and aim
Mesenchymal stromal cells (MSCs) are pluripotent cells that have 
immunosuppressive effects both in vitro and in experimental colitis. 
Promising results of MSC therapy have been obtained in patients with 
severe graft versus host disease of the gut. Our objective was to 
determine the safety and feasibility of autologous bone marrow derived 
MSC therapy in patients with refractory Crohn’s disease (CD).
Patients and intervention
Ten adult patients with refractory CD (8 females/2 males) underwent 
bone marrow aspiration under local anesthesia. Bone marrow MSCs were 
isolated and expanded ex vivo. MSCs were tested for phenotype and 
functionality in vitro. Nine patients received 2 doses of 1-2x106 cells/kg 
bodyweight, intravenously, 7 days apart. During follow up, possible side 
effects and changes in patients’ Crohn's disease activity index (CDAI) 
scores were monitored. Colonoscopies were performed at week 0 and 6, 
and mucosal inflammation was assessed by using the Crohn's disease 
endoscopic index of severity (CDEIS).
 
Results
MSCs isolated from CD patients showed similar morphology, phenotype, 
and growth potential compared to MSCs from healthy donors. 
Importantly, immunomodulatory capacity was intact, as CD MSCs 
significantly reduced peripheral blood mononuclear cell proliferation in 
vitro. MSC infusion was without side effects, besides a mild allergic reaction 
probably due to the cryopreservant DMSO in one patient. Baseline 
median CDAI was 326 (range 224-378). Three patients showed clinical 
response (CDAI decrease ≥70 from baseline) 6 weeks post treatment, 
conversely three patients required surgery due to disease worsening. 
Conclusions
Administration of autologous bone marrow derived MSCs appears safe 
and feasible in the treatment of refractory CD. No serious adverse events 
were detected during bone marrow harvesting and administration. 
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INTRODUCTION
Inflammatory bowel diseases (IBD) are chronic inflammatory disorders of 
the gastro-intestinal tract, including Crohn’s disease (CD) and ulcerative 
colitis. Despite the improvements in IBD management with the 
introduction of anti-TNF compounds, remission often remains difficult to 
maintain. Many patients suffer from a poor quality of life due to disease 
relapse, repeated surgeries, extra intestinal manifestations and drug side 
effects. Therefore, novel therapeutic approaches need to be explored.
Mesenchymal stromal cells  (MSCs) are nonhematopoietic stromal cells 
exhibiting multi-lineage differentiation capacity and the ability to mediate 
immunosuppressive and anti-inflammatory effects.1-3 MSCs are easily 
isolated from various tissues4-6, including the bone marrow, and are capable 
of ex vivo expansion. Moreover, MSCs can be cryopreserved without loss 
of phenotype or differentiation potential.7 Systemic infusion of MSCs 
ameliorated the clinical and histopathologic severity of experimental 
colitis, abrogating body weight loss, diarrhea, and inflammation and 
increasing survival. 8, 9 Moreover, in humans, transplantation of bone 
marrow (bm) derived MSCs has led to improvement of corticosteroid 
refractory graft-versus-host disease (GvHD), including GvHD of the gut10, 
11 and MSCs obtained from adipose tissue induced healing in complex 
perianal fistulas in patients with CD.12 Although the mechanisms underlying 
these effects are not fully elucidated, it has been shown that both cell-cell 
contact and the secretion of growth factors and cytokines are involved.13, 
14 The potential role of MSCs in the modulation of immune responses and 
tissue regeneration aroused interest to use MSCs as a novel cellular 
therapy to treat CD.15 
In this clinical phase I study we evaluated the safety and feasibility of 
intravenous infusion of autologous bmMSCs in refractory CD patients. 
Additionally the functionality of these MSCs was studied focusing on 
culture potential, morphology, cell surface marker profiling, differentiation 
potential and immunosuppressive properties. Finally, the effect of bmMSCs 
on various drugs used to treat CD was assessed.
MATERIAL AND METHODS
Patient selection
On January 14th 2008, the Medical Ethical Committee of the Leiden 
University Medical Center (LUMC) and the Central Committee on 
Research involving Human Subject (CCMO, The Hague, the Netherlands) 
approved this phase I study on autologous bmMSCs in the treatment of 
refractory CD (registered in the Netherlands National Trial Register under 
study number NTR1360 www.trialregister.nl). All patients gave written 
informed consent. Criteria for patient inclusion were that patients were at 
least 18 years of age and had moderate to severe CD, as defined by a 
baseline Crohn’s disease activity index (CDAI) score between 220 and 
450. Furthermore, patients had to be refractory to the standard treatment 
options for CD. We defined refractory patients as patients  that, at some 
time during the course of the disease, must have received steroids, 
immunosuppressive agents (for example, azathioprine, 6-mercaptopurine 
or methotrexate) or anti-TNF therapy which did not result in an adequate 
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response to treatment. The following medications were allowed: 5-
aminosalicylates and corticosteroids (at a stable dosage regimen for at 
least four weeks) and methotrexate, azathioprine, or 6-mercaptopurine (at 
least twelve weeks, with stable dosage regimen for at least eight weeks). 
Infliximab was discontinued at least eight weeks prior to enrolment. All 
patients continued current treatment at the time of infusion. Before bone 
marrow harvest for MSC isolation and expansion, patients were 
thoroughly screened including medical history, physical examination, 
standard laboratory investigations and chest x-ray to rule out tuberculosis. 
Each patient was also screened for human immunodeficiency virus (HIV), 
syphilis, and hepatitis  B and C virus. Patients were excluded if they had a 
history of lymphoproliferative disease or malignancy within the past five 
years, when they exhibited serious infections or when in need of 
immediate surgery. Colonoscopy was performed at baseline to confirm 
disease activity. Laboratory methods for clinical expansion of MSCs
MSC isolation and expansion
MSCs were expanded according to a common protocol devised by the 
European Group for Blood and Bone Marrow Transplantation (EBMT) 
developmental committee, as  previously described.16 Bone marrow was 
harvested by aspiration from the iliac crest from patients under local 
anesthesia in the outpatient clinic. Bone marrow mononuclear cells (MNC) 
were isolated by Ficoll density gradient (density 1.077 g/cm3) 
centrifugation. Washed cells were resuspended in Dulbecco’s modified 
Eagle’s-low glucose medium (Invitrogen, Paisley, UK) supplemented with 
penicillin and streptomycin (Lonza, Verviers, Belgium) and 10% fetal bovine 
serum (FBS, HyClone, Logan, UT) without any additional growth factors. 
MNCs were plated at a density of 160 000 cells per cm².  Cultures were 
maintained at 37ºC in a humidified atmosphere containing 5% CO2 in 175 
cm² flasks (Greiner Bio-One, Frickenhausen, Germany). When the cultures 
reached near confluence (>80%), the cells were detached by treatment 
with trypsin/ EDTA (Lonza, Verviers, Belgium) and replated at a density of 
4000 cells per cm². MSCs were passaged up to a maximum of three times. 
When sufficient MSCs were expanded, cells were harvested and 
cryopreserved in isotonic buffered salt solution supplemented with 10% 
dimethyl sulphoxide (DMSO, LUMC Pharmacy, the Netherlands). Data on 
MSCs obtained from healthy donors matched for age and gender were 
obtained from previous studies.17-19 MSCs for these studies were sourced 
either from a family or non-related (third party) donor. Donors were 
informed about and consented to the possibility of the use of their MSCs 
for preclinical studies/analysis. All donors underwent routine donor control 
examination and screening tests, according to the standard procedures 
required for bone marrow donors. Following eligibility, donors donated 
50-100ml of bone marrow under local anesthesia as described above.
Characterization of MSC products
Morphology was monitored twice a week throughout the culture period by 
light microscopy. Cell viability was determined at each passage and harvest 
procedure by tr ypan blue sta in ing in a Bür ker chamber . 
Immunophenotyping of cultured MSCs was performed using flow 
cytometry. The following markers were analyzed: HLA II (DR), CD73, 
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CD90, CD31, CD34, CD45, CD80 (Becton Dickinson, Franklin Lakes, NJ, 
USA), and CD105 (Ancell, Bayport, MN, USA). The samples were analyzed 
on a FACSCalibur™ using CellQuest Pro software (Becton Dickinson). 
Absence of  contamination by pathogens was tested at culture initiation and 
harvest of the MSC product by aerobic and anaerobic cultures (Becton 
Dickinson, Bactec plus aerobe/F and Bactec plus anaerobe/F). Genetic 
stability of the expanded MSCs was tested by karyotype analysis using a 
standard G-banding procedure. 
Clinical application of MSC products
Release criteria for clinical use of MSCs included product sterility, absence 
of visible cell clumps, spindle-shape morphology, expression of CD73, 
CD90, and CD105 surface molecules (>90%) and a normal karyotype in 
at least 20 observed metaphases.
Laboratory methods for supportive research
In vitro differentiation   
MSCs were plated at 5x104 cells/cm2 in 24-well culture plates and kept in 
complete medium until 80-90% confluency was reached. For osteogenic 
differentiation cells  were stimulated for 21 days in standard medium 
supplemented with 50 μg/mL ascorbic acid, 10 mM β-Glycerolphosphate 
and 10−8M dexamethasone and were stained with Fast Blue  for alkaline 
phosphatase. For adipogenic differentiation, cultures were stimulated for 21 
days with complete medium supplemented with 0.5 mM 3-isobutyl-1-
methylxanthine, 100 uM indomethacin, 5 ug/ml insulin and 10-6 M 
dexamethasone. Lipid droplets were revealed by staining with Oil Red O. 
Control MSCs were grown in non-conditioned medium. All chemicals 
were from Sigma-Aldrich.
MSC/peripheral blood mononuclear cell (PBMC) proliferation assay
Cultured MSCs from CD patients were plated in flat bottom 96 well 
plates (Costar) and allowed to attach overnight. PBMCs were isolated 
from whole blood of CD patients before MSC infusion. PBMCs were 
stimulated with anti-CD28/anti-CD3 coated Dynabeads (1 bead/5 cells, 
Invitrogen) per 1x106 cells and were seeded in Iscove's Modified 
Dulbecco's Media (IMDM) with 5% human serum (Sanquin, the 
Netherlands), 5% FBS and 100 IU/mL IL-2 (LUMC Pharmacy, Leiden, the 
Netherlands) per well. Proliferation was measured by 3H-thymidine 
incorporation. 
Cell bead array cytometric assay. 
Production of TNF-α, IL-1b, IL-10, and IL-6 in MSC/PBMC supernatants, 
colon biopsy homogenates and serum was determined using a cytometric 
bead array kit according to the manufacturer’s instructions (BD 
Biosciences).
Study design
Patients received two doses of MSCs, seven days apart at week 0 and 1. 
Just before clinical application, cryopreserved cells were thawed and cells 
were infused intravenously at a target dose of 1-2x106 cells/kg 
bodyweight. Patients were clinically assessed at weeks 0, 1, 2, 4, 6, and 14. 
At each visit, adverse events were ascertained, concomitant medications 
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were recorded and samples for clinical laboratory evaluations and the 
patients’ CDAI score were obtained.  Colonoscopies were performed at 
week 0 and 6, and mucosal inflammation was assessed using the Crohn's 
disease endoscopic index of severity (CDEIS). The study flow chart is 
depicted in figure 1.
+2w +4w +6w0-4/6w
MSC infusion
Assessment MSC expansion and quality control
+1w
Statistical analysis
Data were analyzed using SPSS (version 16.0, SPSS Inc., Chicago, IL) or 
GraphPad (GraphPad software Inc., La Jolla, CA). Analyses included the 
Kruskall-Wallis test followed by Dunn’s multiple comparisons, two-sided t-
test and Wilcoxon signed-rank test for paired data. P-values <0.05 were 
considered significant. 
RESULTS 
Patients 
In total ten patients (eight females/two males, median age 32.5 and range 
19-42 years) with moderate to severe CD (median CDAI score at 
screening of 299.5 and range 255-442) were included in the study and 
underwent bone marrow aspiration under local anesthesia. Besides some 
local pain at the puncture site afterwards, bone marrow aspiration was 
well tolerated by all patients. Baseline characteristics are presented in table 
1. The bone marrow aspiration procedure resulted in sufficient bone 
marrow to expand MSC up to the required therapeutic doses (Table 2). 
One patient (patient 9), with a CDAI score of 255 at screening, showed no 
active disease on colonoscopy and was therefore excluded for further 
MSC administration. The baseline median CDAI score of the remaining 
nine treated patients was 326 (range 224-378). During MSC infusion, 
patients were closely monitored. MSC infusion was successful and without 
relevant side effects. In one patient a transient mild allergic reaction 
occurred which was probably due to the cryopreservant DMSO. 
Moreover, all patients noticed the typical smell and taste due to the DMSO 
up to 48 hours after infusion. Other adverse events in the first 6 weeks of 
the protocol, such as common cold and headache (Table 3), were ruled 
unlikely to be associated with MSC treatment.
bmMSC from refractory CD patients are comparable to MSCs from 
healthy donors
Approximately hundred milliliters of bone marrow was aspirated from 
each patient and bmMSCs were isolated and cultured. MSCs from CD 
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Figure 1. Study flow chart.
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Patient number 1 2 3 4 5 6 7 8 9 10
Age (y) 24 36 33 34 34 42 29 32 19 30
Sex F F F F F M M F F F
Disease duration (y) 10 5 15 3 11 4 7 12 3 10
CDAI at screening 442 346 283 316 337 237 316 280 255 277
Baseline CDAI 332 341 254 326 350 266 378 224 NA 304
Disease localization ileocolonic colonic, ileum ND colonic, ileum ND ileum ileum colonic colonic, ileum ND colonic, ileum ND no active disease colonic
Perianal disease yes no
yes, perianal abscess 
(inactive)
no yes (inactive) no yes (inactive) no no yes (inactive)
Extra-intestinal manifestations arthralgias arthralgias no arthralgias no no cheilitis granulomatosa no no no
Current medical therapies CS 50mg, AZA MTX, ADA CS 10mg CS 5mg CS 40mg MTX CS 30mg, 6-MP CS 5mg, MTX NA CS 5mg, MTX
Height (cm) 175 167 174 172 158 160 187.5 173 157 161
Weight (kg) 59.3 68.6 74 99.9 46 78 107.5 113.2 50.5 53.1
Current smoker / Smoking history no / no no / no no / no no / yes no / no no / yes yes / yes no / no no / yes no / yes
Prior medical therapies
CS, AZA, IFX, MTX, 
CZP, ADA
5-ASA, CS, AZA, IFX, 
MTX, ADA
5-ASA, CS, ATB, AZA, 
IFX, MTX, CZP, ADA
5-ASA, CS, 6MP, IFX, 
MTX, CZP, ADA
5-ASA, CS, AZA, IFX, 
MTX, CZP, ADA, TAC
CS, AZA, IFX, MTX, 
ADA
5-ASA, CS, AZA, IFX, 
CZP, ADA
5-ASA, CS, AZA, IFX, 
MTX, ADA
5-ASA, CS, ATB, AZA, 
IFX, MTX, CZP, ADA
5-ASA, CS, AZA, IFX, 
MTX, CZP, ADA, 
HSCT
Prior surgeries ileocoecal resection no ileocoecal resection ileocoecal resection
ileocoecal resection, 
colostoma on colon 
transversum
no no no no no
Table 1. Baseline characteristics of included patients. Abbreviations: F female, M male, NA not applicable, ND not determined, 5-ASA mesalamine, CS corticosteroids, AZA azathioprine, 6-MP 6-
mercaptopurine, ATB antibiotics, MTX methotrexate, IFX infliximab, CZP certoluzimab pegol, ADA adalimumab, TAC tacrolimus, HSCT mobilisation phase of hematopoietic stem cell 
transplantation, y years. 
Autologous bone marrow derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phase I study    43
5
1x107
1x106
1x105
1x104
0 10 20 25 30 35 4015
C
um
ul
at
iv
e 
nu
m
be
r
Day number
Figure 2. MSC expansion of CD patients (red) and healthy 
volunteers (black) expressed as theoretical cumulative cell number 
per ml harvested bone marrow. 
Table 2. Overview of bone marrow collection, time needed for MSC culture, and final 
MSC product infused. NA not applicable.
Patient 
number 
ml bone marrow 
collected
Days of 
culture
Passage 
number
Number of cells 
(x106)/kg/infusion
Total number of 
cells infused 
1 120 15 1 1.9 220
2 97 24 2 1.9 260
3 106 24 2 2 300
4 114 16 1 2 400
5 106 24 2 1.6 150
6 111 31 3 0.9 146
7 96 23 2 1.1 240
8 109 34 3 1.5 346
9 100 16 1 NA NA
10 102 27 2 2.1 220
Likely related to MSC infusion n Patient number
   Allergic reaction 1 4
   Typical taste and smell 9 all
   Headache 3 1,4,7
Unlikely related
   Worsening CD* 2 1.7
   Dizziness 1 1
   Nausea 2 1.2
   Vomiting 1 1
   Bloating 1 3
   Abdominal pain 3 3,5,8
   Hemorrhoid 1 4
   Fever 1 4
   Lack of appetite 2 1.4
   Fatigue 2 5.8
   Diarrhea 1 8
   Common cold 1 10
   Otitis media acuta 1 2
Table 3. Adverse events in MSC treated patients 
(week 0-6). Two serious adverse events (*) were 
reported due to worsening of disease requiring 
hospitalization.
  3 
patients showed the typical spindle-shaped morphology and similar growth 
potential and yield compared to MSCs from healthy donors (Figure 2). 
Depending on the number of cells needed and the yield of cells, MSCs 
were harvested in the first, second or third passage (Table 2). All MSC 
cultures showed normal karyotyping. Immunophenotypical characterization 
was performed by FACS analysis  and showed similar phenotyping as 
described for healthy controls (Table 4). Furthermore, CD MSCs were 
able to differentiate along the osteogenic and adipogenic lineages when 
cultured in appropriate culture medium (Figure 3).
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Patient number 1 2 3 4 5 6 7 8 9 10 Average
HLA-DR 5.1 5.7 7.9 5.7 1 5.4 0.8 0.9 5 5.8 4.3
CD31 1.9 2.1 1.7 2.1 1.7 1.1 2.2 1.6 2 2 1.8
CD73 99.9 99.7 99.9 99.6 99.3 99.7 99.9 99.2 90.4 98.1 98.6
CD45 1.3 1.6 1.9 2.1 3.6 1.3 0.9 1.2 1.4 1.3 1.7
CD105 100 99.9 100 100 100 100 100 99.9 99.9 100 100
CD80 3.1 6.2 10.3 18 4.2 3.3 1 0.2 0.3 29.4 7.6
CD90 100 100 99.9 99.9 99.3 99.6 99.8 100 99.8 99.9 99.8
CD34 6 4 4.6 9.5 2.8 5.6 6.5 0.8 10.1 4.3 5.4
Healthy donor 
number 1 2 3 4 5 6 7 8 9 10 Average
HLA-DR 10.5 3.7 0.6 4.2 12.8 10.1 1.4 9.1 5.3 3.1 6.1
CD31 2.6 1.7 2.5 1.7 2.8 2.9 1.7 3.1 0.4 1.8 2.1
CD73 99.4 97.4 99.7 99.2 99.7 96.7 94 96.4 99.4 99.4 98.1
CD45 2.6 0.7 1.4 1.9 1.2 0.6 1.8 1.2 0.6 1.9 1.4
CD105 99.9 99.9 99.8 100 100 99.9 99.9 100 100 99.9 99.9
CD80 1.5 6.6 3.6 6.2 2.2 19.6 19.8 2.2 2.3 3.8 6.8
CD90 99.9 98.9 99.9 99.8 99.9 99.9 99 99.8 100 99.9 99.7
CD34 4.2 1.7 2.9 4 7.1 19.2 6.6 16.5 5.1 4 7.1
Table 4. Flow cytometric analysis (%) of cultured bmMSCs from CD patients and healthy donors matched for gender and age (mean/median age patients 31.3/32.5 and healthy donors 32.1/32.5).
bmMSCs from CD patients suppress immune responses in vitro
In the presence of autologous bmMSCs proliferation of PBMCs was 
reduced in a cell dose-dependent fashion (Figure 4A) and a decreased 
TNF-α production was observed. An increase of IL-1b, IL-6 was seen, as 
well as an increase in the regulatory cytokine IL-10 (Figure 4B). 
Clinical response
Clinical assessment was performed on all patients using CDAI scoring. Two 
patients were excluded before the primary endpoint was met. The first 
patient (patient 1) was a chronic severe steroid refractory patient on the 
waiting list for surgery. Although an initial drop of CDAI score was seen, 
patient was excluded when presented with a CDAI >450 due to poor 
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Figure 3. CD MSCs differentiate into mesenchymal lineages. (A) Adipocyte differentiation was 
demonstrated in MSCs cultured from a healthy donor (hd) and from a CD patient (pt) after 
which cells were stained with Oil Red O to show lipid droplets in the cytoplasm of the cell. 
(B) For osteoblast differentation MSCs were stained with Fast Blue to show alkaline 
phosphatase activity. Non-conditioned MSCs did not stain for Oil Red O. whereas Fast Blue 
gave slight background staining (not shown). 
Figure 4. MSCs significantly inhibit the proliferation of PBMCs and this inhibition is dose-
dependent. (A)  100 000 PBMCs cells were stimulated with anti-CD3/CD28 beads in the 
absence (white column) or presence (black columns)  of indicated numbers of autologous 
MSCs. Proliferation measured by 3H-thymidine uptake (counts/minute) was expressed as a 
percentage of PBMCs proliferation without MSCs for each individual  patient. (B) Cytokine 
production in the supernatants of PBMC cultures and 10 000MSC/100 000 PBMC cocultures. 
Bars represent the mean and SEM of data from 10 patients in triplo. *P< 0.05 for significant 
differences
  3 
general condition and persistent rectal blood loss. Patient 7 was withdrawn 
from the study four days after the first MSC infusion because of continuing 
abdominal aches and bloody diarrhea. In this case infliximab treatment was 
resumed. CDAI scores improved in five patients, clinical response (defined 
as a drop in CDAI>70) was seen in three patients at week 6 (Table 5). 
Remission (CDAI <150) was not achieved in any of the patients. Three 
patients had a reduction of 70 points in CDAI score, this decrease could in 
most cases be ascribed to solid stools and a decrease in soft stool 
frequency. In a period of 14 weeks, three patients required surgery due to 
disease worsening (Table 3). No significant differences in C-reactive protein 
(CRP) levels were seen. 
Endoscopy
Endoscopic improvement, observed by a drop in CDEIS of 10.0 and 24.7 
points, was seen in two patients with extensive CD localized in the colon 
(Figure 5). In the other five patients no significant endoscopic improvement 
was seen between baseline and six weeks post-infusion. At week 0 and 6, 
levels of CD4+, CD8+ and CD4+CD127+ populations were determined 
in biopsies of inflamed mucosa (Figure 6A, left panels). Lower CD4+ T-cells 
and higher CD4+CD127+ regulatory T-cells  were observed at week 6 
when compared to week 0. Cytokine levels of TNF-α, IL-1b, IL-10 and IL-6 
were determined in mucosal biopsies and serum at week 0 and 6. In 
general, cytokine levels went down in the mucosa (Figure 6A right panels), 
whereas an increase of cytokine levels in the serum was seen (Figure 6B). 
DISCUSSION
This phase I study shows that bone marrow harvesting and expansion of 
bmMSCs from refractory CD patients is feasible and that these MSCs are 
similar to MSCs from healthy donors in, for example, plastic adherence, 
spindle-shaped morphology, growth potential (Figure 2), surface marker 
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Patient number 1 2 3 4 5 6 7 8 10
wk 0* First infusion 332 341 254 326 350 266 378 224 304
wk 1  Second infusion 305 281 182 318 306 247 #452 167 ND
wk 6 Primary endpoint #473 185 179 267 314 160  ND 340 354
Surgical resection
In week number 7 NA NA NA 12 NA NA 14 NA
Table 5. Clinical scores of patients at week 0, 1, and 6. In the 6 month follow up period, three patients underwent surgery in indicated week after MSC infusion. *baseline, #withdrawn from study. 
NA not applicable, ND not determined.
expression, lack of hematopoietic markers (Table 4), and differentiation 
capability (Figure 3). In addition, CD MSCs are able to inhibit autologous 
PBMC proliferation and inhibit TNF-α production in vitro (Figure 4). 
Furthermore, autologous bmMSC infusion appears to be safe as 
intravenous MSC infusions were clinically well tolerated. Reported adverse 
events directly related to MSC infusion were a mild and transient allergic 
reaction in one patient and the typical taste and smell of the 
cryopreservant DMSO noticed by all patients (Table 3). 
Although the design of this  study does not allow conclusions on efficacy, 
after two infusions with autologous bmMSCs, endoscopic improvement 
was seen in two patients (Figure 5), while three patients required surgery 
due to worsening of disease (Table 3). Patients included were chronic 
active patients refractory to all currently available medical therapeutic 
options. One could speculate that the immunomodulatory effect of MSCs 
might not be sufficient to induce clinical remission in this category of 
patients. Further (randomized) trials in also less refractory patients are 
therefore warranted 
In order to study the biologic effects of systemic MSC infusion in 
refractory CD patients we analyzed CD4+CD127+ expression on T-cells 
obtained from colonic biopsies and determined cytokine production in 
both colon homogenates and serum. We observed a trend of lower 
CD4+ T-cells and higher CD4+CD127+ regulatory T-cells at week 6 when 
compared to week 0, although the number of patients in this study was 
not enough to reach statistical significance. In addition, cytokine levels went 
down in mucosal biopsies, indicating a decrease in intestinal inflammation 
(Figure 6A, right panels). The apparent reciprocal increase in serum 
cytokine levels (Figure 6B) may be the result of altered distribution of 
inflammatory cells. Due to the decreased local inflammation, leukocytes 
are no longer recruited to the intestine but remain in the circulation, thus 
increasing the systemic cytokine levels. Similar findings have been observed 
for regulatory T-cells  in CD20 and plasmacytoid dendritic cells in dermal 
inflammation.21 
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Figure 5. Endoscopy at week 0 (upper panels) and at 6 weeks (lower panels) after MSC 
treatment (two administrations of 2x106 autologous bmMSCs) shows clear mucosal healing. 
Pictures A and B are from patient 2, pictures C and D from patient 3.
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The intravenous route of administration and target dose of 1-2x106 cells/
kg bodyweight were based on experience with protocols used in GvHD. 
Intravenous infusion of cells is an easy, minimal invasive and routinely 
performed procedure with proven safety so far. Although it has been 
suggested that MSCs home to sites of inflammation, it is  unknown how 
many cells will eventually reach the intestine in CD patients. In a case 
report, Dinesen et al.22 showed that MSCs administration via selective 
mesenteric artery cannulation was safe and feasible. This approach may 
possibly increase the number of cells reaching the affected organ. 
In the case of autologous MSCs, an ongoing discussion is whether MSCs 
are affected by or may contribute to the underlying disease. For instance, 
MSCs from patients with systemic lupus erythematosus are difficult to 
expand in culture and yield low cell numbers23 and those from patients 
with multiple myeloma have been shown to be impaired and possibly 
contribute to the pathogenesis of the disease.24 In this study we 
demonstrate that MSCs obtained from refractory CD patients show 
similar growth potential, yield and properties when studied in vitro in 
comparison to MSCs from healthy donors. Our data support work 
published recently25 and suggest that bmMSCs from refractory CD 
patients are not affected by the disease. Unfortunately, there is no golden 
standard test to assess the functionality of MSCs and it has not been 
demonstrated that in vitro effectiveness of MSCs can be translated to 
clinical effectiveness, making true extrapolation of this topic difficult.
A concern in cell based therapies with ex vivo expanded cells is the 
formation of tumors. Previous work indicated that in mice, MSCs stimulate 
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Figure 6 CD4+, CD8+, and CD4+CD127+ populations in biopsies of inflamed mucosa at 
week 0 and 6 (A, left panels). Cytokine levels of TNF-α, IL-1b, IL-10, and IL-6 were 
determined in mucosal biopsies (A, right panels) and serum (B) at week 0 and 6. Bars 
represent mean and SEM. *P< 0.05 for significant differences.
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the growth of cancers26, 27 and promote metastasis.28 Additionally, 
extensive in vitro expansion of cells may induce genetic instability. 
However, two main works reporting transformation of human MSCs in 
culture were recently retracted as obtained data were based on tumor cell 
contaminated MSC cultures.29 Although an increased risk on tumor 
formation has never been confirmed in humans, patients with a history of 
malignancy were excluded from this study. To minimize the risk of 
transformation of cells we have expanded MSCs in the absence of growth 
factors, plated MSCs in moderate cell concentrations and used only low 
passage numbers. Furthermore, we karyotyped the MSC product before 
clinical release to confirm normal karyotype and did not observe any 
aberrancies.
In conclusion, our data suggest that intravenous application of autologous 
bmMSCs is feasible and well tolerated. Fur thermore, bmMSC 
administration may produce clinical benefits in severe refractory Crohn’s 
disease. Therefore, further studies should be designed to examine MSCs as 
a potential treatment for Crohn’s disease.
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ABSTRACT
Background and aim
Mesenchymal stromal cells  (MSCs) have both multilineage differentiation 
capacity and immunosuppressive properties. Promising results of MSC 
administration have been obtained in experimental colitis. Clinical 
application of MSCs for the treatment of inflammatory bowel diseases 
(IBD) is currently under investigation in phase I-III trials in patients with 
past or concurrent immunomodulating therapy. However, little is known 
about MSC interactions with these immunosuppressive drugs. To address 
this issue we studied the combined effect of MSCs and IBD drugs in in 
vitro functionality assays. 
Methods 
The effects of azathioprine, methotrexate, 6-mercaptopurine, and anti-
TNF-α on MSC phenotype, survival, differentiation capacity, and 
immunosuppressive capacity were studied.
Results
MSC exposed to physiologically relevant concentrations of IBD drugs 
displayed a normal morphology and fulfilled phenotypic and functional 
criteria for MSCs. Differentiation into adipocyte and osteocyte lineages 
was not affected and cells exhibited normal survival after exposure to the 
various drugs. MSC suppression of peripheral blood mononuclear cell 
(PBMC) proliferation in vitro was not hampered by IBD drugs. In fact, in 
the presence of 6-mercaptopurine and anti-TNF-α antibodies, the 
inhibitory effect of this drug alone was enhanced, suggesting an additive 
effect of pharmacotherapy and MSC treatment.
Conclusions
This study demonstrates that in vitro, MSC phenotype and function are 
not affected by therapeutic concentrations of drugs commonly used in the 
treatment of IBD. These findings are important for the potential clinical use 
of MSCs in combination with immunomodulating drugs and anti-TNF-α 
therapy.
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INTRODUCTION 
Currently, mesenchymal stromal cell (MSC) administration is being 
evaluated as a novel treatment modality for Crohn’s disease.1 MSCs are 
pluripotent, non-hematopoietic cells easily isolated from various tissues. In 
the absence of a single specific marker, MSCs are characterized using a 
specific panel of markers. Isolated and expanded MSCs express surface 
molecules CD105, CD73, and CD90 but do not express CD14 and 
hematopoietic surface molecules (CD45 and CD34). Furthermore, human 
leukocyte antigen (HLA)-DR is not expressed unless cells are stimulated 
with interferon gamma (IFN-γ).2 Under appropriate conditions, MSCs can 
differentiate in vitro into different cell types such as adipocytes, 
osteoblasts, and chondroblasts.
Clinical trials with MSCs in patients with Crohn’s disease focus on either 
active luminal disease,1 for which MSCs can be injected intravenously, or 
fistulizing disease, for which MSCs are injected locally into the fistula tracts.
3, 4 MSCs are isolated from bone marrow or adipose tissue either from the 
patient (autologous) or from a healthy donor (allogeneic). In general, 
patients with Crohn’s disease included in the current trials are relatively 
refractory to various immunomodulatory drugs, which may have altered 
their MSCs prior to harvesting (in an autologous setting), or may change 
the function of administered MSCs. Thus far, trials attempt to deal with this 
by stopping anti-TNF-α treatment at least 8 weeks before the application 
of MSCs and restricting other concomitant drugs to a stable dosage 
regimen of immunomodulators, antibiotics or, in the case of fistulizing 
Crohn’s disease, cyclosporine.1, 5 However, scientific data providing 
rationale for (dis)continuation of drugs during MSC treatment have not 
been available yet. 
Previous studies showed that immunosuppressive drugs can be harmful to 
hematopoietic stem cells or endothelial progenitor cell proliferation and 
s i gn i f i cant ly a f fec t the i r funct iona l capac i t ies .6-9 L i kewise , 
immunosuppressive agents might have an effect on MSC function and 
could, therefore, change the outcome of MSC therapy and affect safety. 
Also, allogeneic MSCs are exposed to drugs taken by the patient after local 
or intravenous administration. Furthermore, administered MSCs could 
interfere with concomitant medical therapy. To optimize treatment efficacy 
and safety, it is important to assess the effects of drugs routinely used in 
patients with IBD on the function of MSCs, and vice versa. Therefore, in 
this study, we examined the effect of azathioprine, methorexate, 
6-mercaptopurine and anti-TNF-α (infliximab) on bone marrow-derived 
MSCs, focusing on MSC phenotype, viability and function. Subsequently, we 
studied the effect of MSCs on the immunosuppressive properties of these 
drugs.
MATERIALS AND METHODS
MSC isolation and expansion
Donors underwent routine donor control examination and screening 
tests, according to the standard procedures required for bone marrow 
donors. MSCs from three different donors were expanded according to a 
common protocol devised by the European Group for Blood and Bone 
Marrow Transplantation (EBMT) developmental committee, as previously 
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described.10 Bone marrow was harvested by aspiration from the iliac crest 
from patients under local anesthesia in the outpatient clinic. Bone marrow 
mononuclear cells were isolated by Ficoll density gradient (density 1.077 g/
cm3) centrifugation. Washed cells were resuspended in Dulbecco’s 
modified Eagle’s-low glucose medium (Invitrogen, Paisley, UK) 
supplemented with penicillin and streptomycin (Lonza, Verviers, Belgium) 
and 10% fetal calf serum (FCS, HyClone, Logan, UT), without any 
additional growth factors (hereafter referred to as standard culture 
medium). Mononuclear cells were plated at a density of 160 000 cells per 
cm². Cultures were maintained at 37ºC in a humidified atmosphere 
containing 5% CO2 in 175 cm² flasks (Greiner Bio-One, Frickenhausen, 
Germany). When the cultures reached near confluence (>80%), the cells 
were detached by treatment with trypsin/ EDTA (Lonza, Verviers, Belgium) 
and replated at a density of 4000 cells per cm². Cells were used from 
passage 3 to passage 6. 
IBD drugs
Azathioprine (Sigma-Aldrich, St. Louis, MO), methotrexate (Pharmachemie 
BV, Haarlem, the Netherlands), and 6-mercaptopurine (Sigma-Aldrich) 
were used in relevant physiologic concentrations of 1μM, 100 μg/mL, and 
4μM respectively. Infliximab (Schering-Plough, Houten, the Netherlands) 
was prepared according to the manufacturer’s recommendations. In all 
experiments, azathioprine and 6-mercaptopurine were dissolved in 
dimethyl sulfoxide (DMSO, Sigma-Aldrich), and cells treated with DMSO 
alone were used as control.
The concentrations11-16 used in our experiments are concentrations 
commonly used in in vitro experiments and are therapeutic concentrations 
that are also obtained in vivo.
Flow cytometric analysis 
MSC immunophenotype was analyzed using flow cytometry. MSCs were 
seeded in 25cm2 flasks and were incubated with IBD drugs added to 
standard culture medium for 7 days in total, medium was changed on day 
3. Cells were harvested and immunophenotyping of cultured MSCs was 
performed using flow cytometry for the following markers: CD105, CD73, 
CD90, CD45, CD34, CD14, CD19 and HLA-DR (BD Biosciences, Franklin 
Lakes, NJ). Samples were analyzed using a FACSCalibur flow cytometer 
(BD Biosciences)  and data were analyzed with FlowJo software (version 
7.2.5., Treestar, San Carlos, CA).
Cell viability by MTT assay
MSC were seeded in a 96-well plate at 5000 cells/well and incubated with 
IBD drugs in standard culture medium for 48 hours or 7 days. To 
determine viable cell numbers the MTT assay was used. At the end of the 
experiment, medium was replaced with 100 μL fresh medium, and 25 μL 
of 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT, Sigma-Aldrich) in PBS was added and incubated for 4 hours at 
37°C. DMSO (100μL) was then added and the intensity of color was 
determined at 550 nm using a microplate reader (VersaMax, Molecular 
Devices, Sunnyvale, CA).
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In vitro differentiation
MSCs were plated at 5000 cells/cm2 in 24-well culture plates and kept in 
standard culture medium until 80-90% confluency was reached. For 
differentiation, MSCs were cultured in differentiation medium in the 
presence of the indicated IBD drug. Control MSCs were grown in non-
conditioned medium. For osteogenic differentiation, cells were grown in 
standard medium supplemented with 50 μg/mL ascorbic acid, 10 mM β-
glycerolphosphate, and 10−8M dexamethasone and were stained with Fast 
Blue for alkaline phosphatase activity and Alizarin Red for mineralization. 
For adipogenic differentiation, cultures were stimulated with complete 
medium supplemented with 0.5 mM 3-isobutyl-1-methylxanthine, 100 μM 
indomethacin, 5 μg/ml insulin and 10-6 M dexamethasone. Lipid droplets 
were revealed by staining with Oil Red O. All chemicals were from Sigma-
Aldrich (St. Louis, MO). Cells were kept at 37ºC, 5% CO2 for up to 21 
days and the media were changed twice weekly.
MSC/peripheral blood mononuclear cell (PBMC) proliferation assay
On day 1, cultured MSCs were plated at increasing numbers in flat bottom 
96 well plates (Costar) and allowed to attach overnight. PBMCs were 
isolated from buffy coats,  activated with αCD3/αCD28 coated beads 
(Invitrogen) (1 bead/5 cells) and seeded in Iscove's modified Dulbecco's 
medium (Sigma-Aldrich) containing indicated IBD drug,  5% human serum 
(Sanquin, Leiden, the Netherlands), 5% FCS and 100 IU/mL IL-2 (LUMC 
Pharmacy, Leiden, the Netherlands) at 100 000 per well on day 2. 
Proliferation was measured by 3H-thymidine incorporation on day 7. 
Statistical Analysis
Data were analyzed using SPSS (version 16.0, SPSS Inc., Chicago, IL) and 
GraphPad (Graphpad software Inc., La Jolla, CA). Results are 
representative of at least three independent experiments and show means 
± standard error of the mean unless otherwise indicated. P values were 
calculated using the analysis of variance (ANOVA) and Student’s t-test 
with values less than 0.05 considered statistically significant.
Ethical Considerations
MSCs were obtained from donors in previous studies.10,17,18 Donors were 
informed about and consented to the possibility of the use of their MSCs 
for preclinical studies/analysis. The Medical Ethical Committee of the Leiden 
University Medical Center (LUMC) approved the use of these MSCs for 
preclinical studies. 
RESULTS
MSC phenotype and viability are not affected by drugs commonly used in IBD
For lack of a specific marker identifying MSCs, this cell type is commonly 
identified using a panel of markers as described before.2 In short, MSCs 
are characterized by expression of CD105, CD90, CD73, and the absence 
of hematopoietic markers. To determine whether MSCs retained their 
phenotype after exposure to IBD drugs, cells were grown in culture 
medium in the presence of these drugs. Exposure to either azathioprine, 
methotrexate, 6-mercaptopurines or anti-TNF-α antibodies for seven days 
did not alter MSC morphology and phenotype. These MSCs showed 
normal expression of CD73, CD90, and CD105 and absence of CD45, 
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Figure 1. Effect of IBD drugs on MSC phenotype. Surface markers on control (upper panels) and IBD drug-treated MSCs (lower panels) were analyzed by flow cytometry. Markers are shown 
(solid histogram) compared to isotype control (line).
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CD34, CD14, and CD19 (Figure 1). Furthermore, MSCs did not express 
HLA-DR, indicating they were not activated by the drugs.19 Additionally, 
incubation with IBD drugs for 48 hours (Figure 2A) as well as 7 days 
(Figure 2B) had no effect on the viability of the MSCs.
MSCs maintain their multilineage differentiation capacity in the presence of 
IBD drugs 
Minimal criteria for defining MSCs also include their adherence to plastic 
and the capacity to differentiate into various lineages in vitro, including 
adipocytes and osteocytes. To test the effects of IBD drugs on these 
functions, MSCs were cultured under various differentiation conditions in 
the presence of IBD drugs. MSC adherence to plastic was maintained and 
unaffected by any of the drugs. Also the spindle-shaped fibroblastic 
morphology was not altered (Figure 3A). To determine the effect of IBD 
drugs on MSC differentiation capacity, MSCs were concomitantly cultured 
under adipogenic and osteogenic conditions. MSCs cultured under these 
conditions maintained their capability to differentiate into adipocytes 
(Figure 3B) and osteoblasts (Figure 3C) in the presence of IBD drugs, and 
therefore fulfill the international MSC criteria.
IBD drugs combined with MSCs retain immunosuppressive properties on 
activated PBMCs
MSCs have the capacity to inhibit T-cell proliferation, as previously shown in 
various studies.20-22 We tested the immunosuppressive capacity of the 
MSCs at different ratios to PBMCs stimulated with αCD3/αCD28 coated 
beads. In this setting, PBMC proliferation is inhibited by MSCs in a dose-
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Figure 2. Cell  viability of MSCs exposed to IBD drugs for 48 hours (A) and 7 days (B) as 
measured by MTT assay and expressed as a percentage of untreated control. 
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Figure 3. Differentiation capacity of MSCs into adipocytes and osteoblasts cultured in the presence of IBD drugs. A Control culture-expanded MSC morphology in the presence of IBD drug 
(no staining). B Lipid droplets in the cell cytoplasm of adipocytes were stained with Oil Red O. Magnifications 32x. C Osteogenic differentiation was detected with Fast Blue to show alkaline 
phosphatase activity and Alizarin Red to detect mineralization. Magnifications 10x.
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dependent manner (Figure 4A). Next, we examined if MSCs would have a 
positive or negative effect on the immunosuppressive properties of 
azathioprine, methotrexate, and 6-mercaptopurine in vitro. We found that 
MSCs did not antagonize the effect of the immunomodulating drugs on 
PBMC proliferation. Azathioprine and methotrexate alone inhibit PBMC 
proliferation, as has been described previously.23, 24 This effect was 
enhanced when MSCs were present in the culture, although this did not 
reach statistical significance (Figure 4B). Presence of MSCs in co-cultures 
containing 6-mercaptopurine did show a significant additive effect, with a 
decrease in PBMC proliferation of 53.5% (no MSCs 82.4 ± SD 7.1 vs 1000 
MSCs 28.9 ± SD 6.0, P<.001).
It has been described that MSCs need to be stimulated by pro-
inflammatory cytokines, e.g. IFN-γ and TNF-α,  to exer t their 
immunosuppressive effect.25,26 By adding anti-TNF-α agents to PBMC 
cultures, TNF-α activity is neutralized,27 thereby possibly affecting MSC 
function. Therefore, we analyzed the effect of increasing concentrations of 
the anti-TNF-α agent infliximab on MSC/activated PBMC co-cultures. In 
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Figure 4. MSC and IBD drug interactions on PBMC proliferation.  A MSCs inhibit the proliferation of 
activated PBMCs in a dose-dependent fashion. PBMCs (100 000 cells) were stimulated with αCD3/αCD28 
beads and cocultured with different numbers of MSCs. B Effect of IBD drugs on the proliferation of PBMCs 
(100 000 cells) stimulated with αCD3/αCD28 beads in the presence of different numbers of MSCs (0, 
1000 and 10 000). C Effect of increased concentrations of infliximab on the proliferation of PBMCs (100 
000 cells)  stimulated with αCD3/αCD28 beads in the presence of indicated number of MSCs (0, 1000, 
5000 and 10 000). Proliferation was measured by 3H-thymidine uptake in counts per  minute. Data are 
expressed as a percentage relative to PBMC proliferation in control  medium (set to 100%).and presented 
as means ± SEM,*P<0.05, **P<0.01, ***P<.001.
this setting, inhibition of PBMC proliferation by MSCs persists also in the 
presence of high concentrations (50 and 100 μg/mL) of infliximab (Figure 
4C), indicating that neutralization of TNF-α alone is insufficient to 
antagonize MSC function.
DISCUSSION
Currently, MSC administration is being evaluated as a potential new 
treatment for Crohn’s disease. Studies in experimental colitis have 
generated promising results,28-30 and phase I studies have not shown any 
major safety and feasibility concerns.1, 3 At the moment, various phase II 
trials are undertaken attempting to optimize MSC treatment with regard 
to dosage, timing, and route of administration. However, the effect of 
concomitant use of various IBD drugs is unknown and raises questions on 
which patients to include in the various trials. Patient MSCs might be 
affected by past drug usage but also allogeneic MSCs are exposed to 
immunomodulating drugs after administration. Therefore, we first aimed to 
study the effects of commonly used IBD drugs on MSC phenotype and 
function. Subsequently, the effect of MSCs on the immunosuppressive 
properties of these drugs was studied.
This study demonstrates that MSCs exposed to IBD drugs fulfill the 
minimal set of standard criteria introduced by the Mesenchymal and Tissue 
Stem Cell Committee of the International Society for Cellular Therapy,2 
indicating that these drugs do not substantially change MSC morphology, 
phenotype, and differentiation capacities. Furthermore, MSC viability was 
not affected by any of the compounds examined.
MSCs inhibit PBMC proliferation in a dose-dependent manner.21 
Previously, it was demonstrated that bone marrow derived MSC have a 
synergistic effect with the calcineurin inhibitor cyclosporin on the activation 
of cytotoxic T cells.31-33 Conversely, MSCs derived from heart tissue 
decreased the immunosuppressive effect of tacrolimus and rapamycin, 
r a i s ing some concern regard ing the s imu l taneous use o f 
immunomodulating drugs and MSC treatment.34  Although cyclosporin and 
tacrolimus are used in the controlling IBD, they are still of limited value as 
randomized controlled studies are lacking.35, 36 This chapter mainly focused 
on immunomodulating drugs frequently used in the treatment of IBD and 
we found that, in vitro, bone marrow-derived MSCs do not hamper the 
inhibitory effect of these drugs. Furthermore, we show that neutralization 
of TNF-α using the anti-TNF-α agent infliximab does not antagonize the 
inhibitory effect of MSCs. These findings indicate that in the setting of IBD, 
concomitant drug usage may not present a problem for MSC therapy and, 
conversely, that MSC administration does not appear to hamper the 
effects of other drugs. These observations may expand the scope for MSC 
therapy in IBD, as patients unable or unwilling to stop their therapeutic 
regimen, who are now excluded from the various studies, may yet become 
candidates in future trials.
The present study demonstrates that therapeutic concentrations of 
immunosuppressive drugs do not affect MSC phenotype and function. 
These findings are important for the potential clinical use of MSCs in 
combination with immunosuppressants and could further optimize current 
treatment developmental programs.
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Pretreatment with interferon-gamma enhances the 
therapeutic activity of mesenchymal stromal cells in 
animal models of colitis
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ABSTRACT
Mesenchymal stromal cells (MSCs) are currently under investigation for 
the treatment of inflammatory disorders, including Crohn’s disease. MSCs 
are pluripotent cells with immunosuppressive properties. Recent data 
suggest that resting MSCs do not have significant immunomodulatory 
activity, but that the immunosuppressive function of MSCs has to be 
elicited by interferon-gamma (IFN-γ). In this article, we assessed the effects 
of IFN-γ prestimulation of MSCs (IMSCs) on their immunosuppressive 
properties in vitro and in vivo. To this end, we pretreated MSCs with IFN-γ 
and assessed their therapeutic effects in dextran sodium sulfate (DSS)- and 
trinitrobenzene sulfonate (TNBS)- induced colitis  in mice. We found that 
mice treated with IMSCs (but not MSCs) showed a significantly attenuated 
development of DSS-induced colitis. Furthermore, IMSCs alleviated 
symptoms of TNBS-induced colitis. IMSC-treated mice displayed an 
increase in body weight, lower colitis scores, and better survival rates 
compared to untreated mice. In addition, serum amyloid A protein levels 
and local proinflammatory cytokine levels in colonic tissues were 
significantly suppressed after administration of IMSC. We also observed 
that IMSCs showed greater migration potential than unstimulated MSCs to 
sites within the inflamed intestine. In conclusion, we show that 
prestimulation of MSCs with IFN-γ enhances their capacity to inhibit Th1 
inflammatory responses, resulting in diminished mucosal damage in 
experimental colitis. These data demonstrate that IFN-γ  activation of 
MSCs increases their immunosuppresive capacities and importantly, their 
therapeutic efficacy in vivo.
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INTRODUCTION 
Mesenchymal stromal cells  (MSCs) are multipotent cells present in virtually 
all tissues of the body.1 In addition to their function as progenitor cells, 
MSCs have been found to have significant immunosuppressive capacities.2-4 
Recent data suggest that resting MSCs do not have immunomodulatory 
activity, but when activated by IFN-γ, MSCs develop their full 
immunosuppressive potential.5, 6 IFN-γ-activated MSCs secrete large 
amounts of chemokines to attract T-cells and inhibit T-cell proliferation and 
proinflammatory cytokine production.6 Different mechanisms have been 
proposed that describe how this suppression of T-cell activity might be 
mediated. In humans, IFN-γ-induced indoleamine 2,3-dioxygenase (IDO) 
expression appears to be important,7 whereas the expression of inducible 
nitric oxide synthase (iNOS) may be more crucial in mice. MSCs lacking 
the IFN-γ receptor or iNOS are incapable of inhibiting disease progression 
in a mouse model of graft-versus-host disease (GvHD).8, 9 However, 
pretreatment of MSCs with IFN-γ was found to prevent the development 
of murine GvHD more efficiently than unstimulated MSCs.9
Due to their immunomodulatory properties, much interest has focused on 
investigating MSCs as a potential treatment for inflammatory disorders.10 In 
fact, transplantation of MSCs has already been successfully used for 
treating GvHD.11-15 We recently demonstrated that MSC administration is 
safe and feasible in patients with refractory Crohn’s disease,16 and various 
ongoing studies are aimed at evaluating the proper dose and mode of 
administration needed for effective results. Alternatively, potentiation of 
MSC effector mechanisms may improve the efficacy of anti-inflammatory 
treatment. Given the central role of IFN-γ activation on the 
immunosuppressive potential of MSCs, we examined the effect of IFN-γ 
pretreatment of MSCs in two mouse models of colitis. 
MATERIAL AND METHODS 
Mesenchymal stromal cell isolation 
Human bone marrow
MSCs were expanded following a previously described protocol 
developed by the European Group for Blood and Bone Marrow 
Transplantation (EBMT).14 In brief, bone marrow was harvested from 
patients undergoing orthopedic surgery. Bone marrow mononuclear cells 
(MNCs) were isolated by Ficoll density gradient centrifugation (density: 
1.077 g/cm3). Cells were then washed and resuspended in low-glucose 
Dulbecco’s Modified Eagle Medium (Invitrogen, Paisley, UK) supplemented 
with penicillin and streptomycin (Lonza, Verviers, Belgium) and containing 
10% fetal bovine serum (FBS, HyClone, Logan, UT) without any additional 
growth factors. MSCs were plated at a density of 160,000 cells per cm². All 
sampling procedures were performed in accordance with the Helsinki 
Declaration and were approved by the ethics committee of Leiden 
University Medical Center (LUMC). All patients provided informed 
consent.
Mouse bone marrow
MSCs were isolated from 8- to 10-week-old BALB/c mice (Harlan 
Laboratories, Horst, the Netherlands). Femoral heads and condyles were 
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removed and bone marrow was flushed. Cells were plated in alpha-
minimum essential medium (alpha-MEM, Lonza) supplemented with 
penicillin and streptomycin (Lonza), 3 mM L-glutamine (Invitrogen) and 
10% FBS (Invitrogen). After 24 hours, non-adherent cells  were removed. 
Adherent cells were washed with phosphate-buffered saline (PBS), and 
medium was changed every 3-4 days. Animal procedures were carried out 
in compliance with the Institutional Standards for Humane Care and Use 
of Laboratory Animals. All experiments were approved by the Animal Care 
and Use Committee of the LUMC.
MSC expansion and preparation
Cultures were grown in 175 cm² flasks (Corning Life Sciences B.V., 
Schiphol-Rijk, the Netherlands) in a 37ºC humidified incubator containing 
5% CO2. When the cultures reached >80% confluence, cells were 
trypsinized (trypsin/EDTA; Lonza) and replated at a density of 4000 cells 
per cm². MSCs were passaged no more than five times prior to use. To 
generate IFN-γ-prestimulated MSCs (hereafter referred to as IMSCs), cells 
were plated at the same density in media supplemented with either 500 
U/mL recombinant human IFN-γ (Sigma-Aldrich, St Louis, Missouri, USA) 
or murine IFN-γ (PeproTech, Rocky Hill, NJ). Immunophenotyping of 
cultured MSCs was performed using flow cytometry for the following 
markers: MHCII, CD73, CD90, CD14, CD34, CD45, CD19 and CD105 
(BD Biosciences, Franklin Lakes, NJ, USA). Samples were analyzed using a 
FACSCalibur flow cytometer (BD Biosciences), and data were analyzed 
with FlowJo software (version 7.2.5., Treestar, San Carlos, CA, USA). 
In vitro differentiation
MSCs were plated at a density of 5x104 cells/cm2 in 24-well culture plates 
and kept in complete medium until cells reached 80-90% confluency. For 
osteogenic differentiation, cells were stimulated for 21 days in standard 
medium supplemented with 50 μg/mL ascorbic acid, 10 mM β-
glycerolphosphate and 10−8 M dexamethasone and then stained for 
alkaline phosphatase with Fast Blue (Sigma-Aldrich). For adipogenic 
differentiation, cultures were stimulated for 21 days with complete medium 
supplemented with 0.5 mM 3-isobutyl-1-methylxanthine, 100 μM 
indomethacin, 5 μg/mL insulin, and 10-6 M dexamethasone (Sigma-
Aldrich). Lipid droplets were visualized by Oil Red O staining. For 
chondrogenic differentiation, MSCs were grown in serum-free, high-
glucose Dulbecco's Modified Eagle Medium (Invitrogen) medium 
containing 50 μg/mL L-ascorbic-2-phosphate, 40 μg/mL L-proline and 100 
μg/mL sodium pyruvate (Sigma-Aldrich) and supplemented with insulin-
transferrin-selenium (ITS)+ culture supplement (BD Biosciences), 10 ng/
mL transforming growth factor (TGF)-β1 (R&D systems, Abingdon, United 
Kingdom), 10-7 M dexamethasone (Sigma-Aldrich) and 500 ng/mL bone 
morphogenetic protein (BMP)-2 (R&D systems). Cells were stained with 
Toluidine blue to confirm chondrogenic differentiation.
RNA isolation and quantitative pcr
RNA was isolated using the RNAeasy mini kit (Qiagen, Hilden, Germany) 
and cDNA was generated using RevertAid reverse transcriptase 
(Fermentas, St Leon-Rot, Germany) and random hexamer primers 
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(Promega, Leiden, The Netherlands). Quantitative pcr reactions were 
carried out using Invitrogen primers for IDO (forward GATGAAG 
AAGTGGGCTTTGC, reverse CAGGCAGATGTTTAGCAATGA) and 
SybrGreen PCR Kit (Qiagen). For relative expression, data were 
normalized against expression of the household gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH).
Measurement of inducible NOS (iNOS)
iNOS levels were measured in cell lysates using the PathScan Total iNOS 
Sandwich ELISA Kit (Cell Signaling Technology, Bioké, Leiden, the 
Netherlands) following the manufacturer’s instructions.
MSC/peripheral blood mononuclear cell (PBMC) proliferation assay
Cultured human MSCs were plated in 96-well flat-bottom plates (Corning) 
and allowed to adhere overnight. Human PBMCs isolated from buffy coats 
were stimulated with anti-CD28/anti-CD3-coated Dynabeads (1 bead/5 
cells, Invitrogen) and were seeded in Iscove's Modified Dulbecco's Media 
(IMDM, Invitrogen) supplemented with 5% human serum (Sanquin, the 
Netherlands), 5% FBS and 100 IU/mL interleukin (IL)-2 (LUMC Pharmacy, 
Leiden, the Netherlands). Transwell experiments were performed using 
0.2μm membrane inserts (Nunc, Denmark). Cell proliferation was 
measured by 3H-thymidine incorporation.
Induction of colitis and study design
Animals were housed in individually ventilated cages and supplied with 
drinking water and food ad libitum. Experiments were conducted using 6- 
to 8-week-old female mice. For dextran sulfate (DSS)-induced colitis, 
C57BL/6JIco mice (Charles River, the Netherlands) were supplied with 
drinking water supplemented with 2.25% (w/v) DSS (MW 36 000-50 000 
kDa; MP Biomedicals, Illkirch, France) for seven days. On day 0, mice were 
injected intraperitoneally with 0.5x106 human MSCs diluted in 100 μL 
PBS, 0.5x106 human IMSCs diluted in 100 μL PBS or a vehicle control 
(PBS alone). All mice were sacrificed on day 9 after the start of the 
experiment (Figure 1A). 
Trinitrobenzene sulfonate (TNBS, Sigma-Aldrich) colitis  was induced in 
BALB/c mice (Harlan Laboratories, Netherlands). To study the therapeutic 
effect of MSCs on established colitis, mice were presensitized through the 
skin on day 0. On day 7, 2.75 mg TNBS  diluted in 40% ethanol was 
injected intrarectally (4 cm from the  anus) using a 22 G catheter 
(Abbocath, Hospira Benelux, Brussels, Belgium). Six hours after the second 
TNBS instillation, mice were injected intraperitoneally with 1.0x106 mouse 
MSCs, 1.0x106 mouse IMSCs or PBS alone. All mice were sacrificed on day 
9 (Figure 1B). For survival analysis, an additional cohort of BALB/c mice 
was treated intrarectally with 3.25 mg TNBS diluted in 40% ethanol on 
days 0 and 6. In this case, mice were injected intraperitoneally with 1.0x106 
mouse MSCs, 1.0x106 mouse IMSCs or PBS alone 6 hrs after the first 
TNBS instillation (Figure 1C). 
Assessment of inflammation
Body weights were recorded daily and wasting disease progression was 
calculated by percentage of weight loss from initial body weight. Animals 
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were withdrawn from the study when weight loss was >20% compared to 
that on day 0 or when weight loss was >10% within 24 hours. 
Blood  samples were collected by cardiac puncture immediately upon 
sacrifice; serum was separated by centrifugation (10 000 x g for 10 min) 
from whole blood and stored at -20°C until use. Colons were removed 
and opened longitudinally. Two independent investigators blinded for 
treatment allocation scored the colons for the presence of loose stool, 
visible fecal blood, and macroscopic inflammation using a scale of 0 to 3 
per item with a maximum score of 9, as previously described.17 Tissue 
weights were recorded and used as an index of disease-related intestinal 
wall thickening. Colons were subsequently divided longitudinally into two 
parts: one part was immediately frozen in  liquid nitrogen  for protein 
extraction and cytokine determination, while the second part was stored 
in formalin and embedded in paraffin for (immuno)histological evaluation.
Histological analysis 
Colonic segments were fixed in 10% neutral buffered formalin, serially 
dehydrated, cleared in xylene, and embedded in paraffin wax. Sections 
(4 µm thick) were collected on coded slides, stained with hematoxylin and 
eosin (H&E), and then independently and blindly scored by an experienced 
pathology resident. The histology damage score was calculated using the 
following criteria: (1) percentage of area involved, (2) number of follicle 
aggregates, (3) edema, (4) fibrosis, (5) erosion/ulceration, (6) crypt loss, and 
infiltration of (7) mononuclear and (8) polymorphonuclear cells. The 
percentage of area involved and crypt loss were scored on a scale of 0 to 
4 (0, normal; 1, <10%; 2, 10%; 3, 10-50%; 4, >50%). Erosions were defined 
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Figure 1. Schematic overview of experimental colitis experiments. 
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as 0 if the epithelium was intact, 1 if the lamina propria was involved, 2 if 
ulcerations involved the submucosa, and 3 when ulcerations were 
transmural. The severity of the other parameters was scored on a scale of 
0 to 3 (0, absent; 1, weak; 2, moderate; 3, severe). The histology damage 
score ranged from 0 points to a maximum of 26 points.18
Immunohistochemistry
T-cells  were detected using an anti-CD3 antibody (1:1000, 
DakoCytomation BV, Eindhoven, the Netherlands). In brief, slides were 
incubated in 0.3% H2O2/methanol for 15 minutes at room temperature. 
After antigen retrieval, slides were blocked with Teng-T (10 mmol/L Tris, 
pH 8.0, 5 mmol/L EDTA, 0.15 mol/L NaCl, 0.25% gelatin, 0.05% (v/v) 
Tween-20) for 30 minutes and followed by overnight incubation at 4°C 
with primary antibody in PBS containing 0.1% Triton X-100 and 1% bovine 
serum albumin (BSA). Primary antibodies were detected using an avidin-
biotin detection system. Secondary antibodies were obtained from 
DakoCytomation BV (1:200) (anti-rabbit, E0432), diluted in PBS 
containing .01% Triton-X and 1% BSA and incubated for 1 hour at room 
temperature. Slides then were incubated for 30 minutes with horseradish-
peroxidase (HRP)-conjugated streptavidin-biotin (DakoCytomation BV). 
Antibodies were detected using the PowerVision Plus Poly-HRP detection 
system from Immunologic (DPVB + 110 HRP, Duiven, the Netherlands), 
and peroxidase activity was detected with Fast 3.3’-diaminobenzidine 
tablets (Sigma-Aldrich). Sections were counterstained with hematoxylin, 
dehydrated, and mounted in Pertex (Histolab Products AB, Göteborg, 
Sweden). Slides were analyzed and scored using ImageJ software (http://
rsb.info.nih.gov/ij/).
Cytokine measurements
Cytokine levels were determined in  colon  mucosa. Colon homogenates 
were obtained using a Potter-Elvehjem glass homogenizer at 4°C in four 
volumes of Greenberger lysis buffer (150 mM NaCl, 15 mM Tris, pH 7.4, 
1 mM MgCl2, 1% Triton X-100) supplemented with protease inhibitors 
(Roche, Almere, the Netherlands). Samples were centrifuged at 
30 000 x g  for 10 minutes at 4°C and stored at −80°C until cytokine 
determination. Protein content was determined using the BCA Protein 
Assay (Thermo Scientific Pierce, Etten-Leur, the Netherlands), and cytokine 
levels in homogenates were measured using the Cytometric Bead Array 
System (BD Biosciences) following the manufacturer’s instructions. 
Serum amyloid A (SAA) levels in mouse serum  samples were measured 
using a commercial ELISA kit (Invitrogen). 
Cell labeling with 99mTc-tropolon 
To analyze the biodistribution and compare homing of MSCs and IMSCs, 
1.0x106 human (I)MSCs were labeled with technetium-99m (99mTc) and 
intraperitoneally injected into different groups of animals on day 7 (n=3) 
(Figure 1D). In brief, human MSCs were washed twice with PBS by 
centrifugation in a two-step washing process (5 minutes at 150 x g). Cell 
labeling with technetium-99m was performed according to a leukocyte-
labeling method that had been modified for stem cells.19, 20  Ten milliliters 
of a 50 mg/mL 2-hydroxy-2,4,6-cycloheptatrienone solution (tropolone, 
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Aldrich Chemical Co., Milwaukee, WI, USA) was first dissolved in ethanol 
and then diluted in saline to 20% (v/v). A solution of SnCl2 (950 mg/L 
SnCl2.2H2O and 2 g/L sodium pyrophosphate.10H2O) was obtained from 
a TechneScan® PYP® kit (Tyco Healthcare Mallinckrodt Medical BV, 
Petten, the Netherlands). KBH4 (crystalline, Sigma, St. Louis, MO) was 
dissolved in 4 M NaOH and diluted with 0.1 M NaOH to a final 
concentration of 10 mg/ml. A lipophilic reactive complex was prepared by 
adding tropolone to a solution of SnCl2 in a ratio of 2:1, which was then 
added to a solution of KBH4 and 99mTc-sodium pertechnetate (200-500 
MBq/mL, Technekow, Tyco Healthcare-Mallinckrodt Medical BV, Petten, the 
Netherlands). Two hundred microliters of the lipophilic reactive complex 
was immediately added to the cell pellet (containing 2x105-2x106 cells) 
and gently shaken for 1 hour at 20oC. Labeled cell solutions were then 
centrifuged in a two-step washing process with PBS to remove non-cell-
related (radioactive) reactants. To determine labeling efficiency, radioactivity 
in the final cell pellet and supernatant was measured using a dose 
calibrator (VDC 101, Veenstra Instruments, Joure, the Netherlands). 
Labeling yields ranged from 34-58%, and the stability of the complex was 
>90% for 24 hours in serum at 37ºC. Animals were sacrificed 24 hours 
after injection of radiolabeled (I)MSCs in established colitis models, and 
relevant organs and tissues were excised, weighed, and measured for 
radioactivity using a dose calibrator. These values were calculated in 
relation to the percentage of the total dose of radioactivity administered 
(%ID/g tissue). 
Microarray analysis
Human MSCs obtained from four individual subjects were treated with 
IFN-γ or left untreated for 6 days. RNA was isolated as described above, 
labeled using the Illumina TotalPrep RNA amplification kit (Ambion, Austin, 
TX) and hybridized to Ref12v3 Arrays. Data were quantile normalized and 
analyzed using Genome studio and Mayday software.21 
Statistical analysis
Data are presented as mean ± standard error of the mean (SEM) using 
two-sided t-tests and the Kruskal-Wallis test followed by Dunn’s post hoc 
test for multiple comparisons. The Kaplan-Meier log-rank test was used to 
analyze survival curves.  All analyses were performed using the SPSS 
statistical package (version 16.0, SPSS Inc., Chicago, IL) and GraphPad 
Prism software (version 5.01). P  < .05 was considered statistically 
significant.
RESULTS
Pretreatment of MSCs with IFN-γ increases immunosuppression 
Given the significant induction of various immune-related proteins by IFN-
γ, we first examined whether MSCs continued to fulfill the minimal criteria 
for defining MSCs even after IFN-γ exposure.22 Human MSCs cultured for 
6 days in the presence of IFN-γ retained their capacity to adhere to plastic 
(data not shown). As previously described,23-25 human MSCs increased the 
expression of major histocompatibility complex (MHC) class II genes in 
response to IFN-γ treatment (Figure 2A), whereas the expression of other 
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Figure 2.  Effect of IFN-γ stimulation on MSC phenotype and function. A. Surface markers for MHC class II on unstimulated (upper panel) and IFN-γ-stimulated human MSCs (lower panel), as 
analyzed by flow cytometry. Markers are shown (solid histogram) compared to isotype control (line). B. Differentiation capacity of human MSCs (upper panels) and IMSCs (lower panels) into 
osteoblasts, adipocytes and chondroblasts. Osteogenic differentiation was detected with Fast Blue to show alkaline phosphatase activity (a, d). Lipid droplets in the cell  cytoplasm were stained 
with Oil Red O (b, e). Toluidine blue staining corresponds with chondrogenesis (c, f). Magnifications, 10x (a, b, d, e); 32x (c, f). C. IFN-γ dependent relative IDO expression in human MSCs (left 
panel). Data are presented as means ± SEM; ** P < .001. D. IFN-γ treatment of mouse MSCs stimulates expression of iNOS (right panel). Data are presented as means ± SEM; * P < .05. 
E. Human IMSCs inhibit the proliferation of activated PBMCs in a dose-dependent fashion. PBMCs (100 000 cells)  were stimulated with anti-CD3/CD28 beads and cocultured with MSCs 
(white columns)  or IMSCs (black columns) in various ratios (PBMC:(I)MSC). Proliferation was measured by 3H-thymidine uptake in counts per minute and is expressed as a percentage of 
PBMC proliferation in the absence of MSCs. Data are presented as means ± SEM; *** P < .001.
markers in the MSC panel were unaffected (Figure 3). Furthermore, IMSCs 
maintained their in vitro differentiation capacity to form osteoblasts, 
adipocytes and chondroblasts (Figure 2B). In addition, we confirmed that 
IFN-γ stimulation leads to elevated IDO expression in human MSCs by 
RT-PCR (Figure 2C), and in increased iNOS levels in mouse MSC lysates 
(Figure 2D). At a functional level, human IMSCs significantly inhibited PBMC 
proliferation at lower PBMC:(I)MSC ratios compared to untreated MSCs, 
indicating that IMSCs have higher immunomodulatory capacities (Figure 
2E). 
IMSCs attenuate the development of DSS-induced colitis
Given the augmented immunosuppressive properties of IMSCs in vitro, we 
examined the anti-inflammatory effects of human IMSCs in vivo using a 
DSS-induced colitis  model. Mice were intraperitoneally injected with 
human MSCs, IMSCs or PBS at the start of DSS induction (day 0). On day 
9 (upon sacrifice), IMSC-treated mice showed significantly reduced weight 
loss compared to PBS-treated mice (Figure 4A). No differences in body 
weight were observed between MSC- and PBS-treated animals. Colons 
were assessed for the presence of loose stool, bleeding and macroscopic 
inflammation (Figure 4B). IMSC-treated (but not MSC-treated) mice had a 
significantly decreased disease score when compared with PBS-treated 
mice (Figure 4C). The PBS-treated group clearly exhibited a severe 
mucosal mononuclear cell infiltrate and disruption of crypt architecture 
(epithelial ulcerations and loss of goblet cells), whereas DSS-induced 
lesions were partially prevented in the IMSC-treated group (Figure 4D). 
These observations were also reflected by the histology scores 
(Figure 4E). These data consistently demonstrate that IMSCs are effective 
in the prevention of DSS-induced colitis. 
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Figure 3. Effect of IFN-γ stimulation on MSC phenotype. Surface markers on unstimulated 
(upper panels) and IFN-γ-stimulated human MSCs (lower panels) were analyzed by flow 
cytometry. Markers are shown (solid histogram) compared to isotype control (line). 
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Figure 4. IMSCs prevent wasting disease progression in DSS-
induced colitis. Mice received 2.25% DSS dissolved in drinking 
water for seven days. On day 0, mice were injected with human 
MSCs, IMSCs or PBS alone. Clinical evolution was monitored by 
body weight changes, macroscopic and microscopic scores. All 
mice were sacrificed on day 9. Data represent mean ± SEM; n=11 
mice per group. A. Body weight changes during the course of the 
experiment. The values of body weight change are expressed as a 
percentage of initial body weight on day 0. *P < .05 compared to 
PBS treatment. B. Macroscopic images of representative mouse 
colons harvested on day 9. C. Macroscopic disease scores based 
on the presence of loose stool, bleeding and macroscopic inflam-
mation determined on day 9 upon sacrifice. **P < .001. D. Histo-
logical  evidence that IMSCs prevent DSS-induced pathology. 
Photomicrographs (20x magnification) of an H&E-stained paraffin 
section of a representative mouse colon from each treatment 
group. E. Histology scores were derived from microscopic analy-
ses of longitudinal colon sections from each mouse.
IMSCs alleviate TNBS-induced colitis
We next examined the effects of IMSC administration on acute Th1-
mediated colitis in mice. The therapeutic effect of mouse IMSCs was 
assessed after skin sensitization on day 0, followed by intrarectal TNBS 
challenge on day 7. Six hours after TNBS challenge, mice received an 
injection of mouse MSCs, IMSCs or PBS. Body weight, colon weight and 
length, as well as macroscopic signs indicative of colonic inflammation were 
determined upon sacrifice (Figure 5A, page 78). TNBS-induced colitis 
resulted in a body weight loss of 4.9% in PBS-treated animals. MSC-treated 
mice displayed an average decrease of 1.3% in body weight, whereas 
IMSC-treated mice had gained 2.5% (Figure 5B). This  body weight increase 
was reflected in a lower disease score (Figure 5C) and a decreased colon 
weight-to-length ratio (Figure 5D). Histological grading showed that the 
IMSC group exhibited diminished severity of colitis (Figure 5E), primarily as 
a result of lower levels of inflammation, less crypt loss, and reduced 
number of granulocytes and mononuclear cells. Histochemistry 
demonstrated prominent infiltration of mononuclear cells into the affected 
colons, particularly in severely damaged regions. Immunohistochemistry 
showed that CD3+ cells (T-cells) were predominantly located in regions of 
inflammation (Figure 5F), and that IMSC treatment appeared to reduce the 
number of T-cells.
For survival analysis, a rectal enema of TNBS was applied to BALB/c mice 
on days 0 and 7. Mouse MSCs, IMSCs or PBS alone was injected 
intraperitoneally 6 hours after the first TNBS administration. Injection of 
either MSCs or IMSCs similarly increased the survival of BALB/c mice after 
TNBS-induced colitis (Figure 6).
IMSCs reduce systemic markers of inflammation
We next examined the influence of IMSCs on serum amyloid A (SAA) 
levels. SAA is a systemic marker of inflammation similar to C-reactive 
protein (CRP) in humans. We detected high SAA levels in serum isolated 
from PBS-treated mice, which corresponded to the severe colitis seen in 
these animals. In contrast, treatment with mouse IMSCs resulted in 
significantly lower SAA serum levels, confirming the decreased 
inflammatory responses observed in these animals (Figure 7A).
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Figure 6.Treatment with mouse MSCs and IMSCs improves the survival  of Balb/c mice with 
TNBS-induced colitis. Colitis was induced by intrarectal  injection of TNBS in Balb/c mice. Mice 
were injected intraperitoneally with MSCs, IMSCs or PBS alone on day 0, starting 6 h after 
intrarectal  TNBS administration. Survival (Kaplan-Meier  analysis) was compared between 
(I)MSC- and PBS-treated animals. n=11 mice per group; *P = .012.   5 
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Figure 5. IMSCs alleviate TNBS-induced colitis. Mice were sensitized through the skin on day 0, challenged intrarectally on day 7, and received mouse MSC, IMSC or PBS injections 6 hrs after 
challenge. Disease progression was assessed by changes in daily body weight as well as macroscopic and microscopic scores on day 9 upon sacrifice. Data are presented as mean ± SEM; 
n=11 mice per group. A. Macroscopic images of representative mouse colons. B. Animal  body weight change on day 9 upon sacrifice. The values of body weight are expressed as a percentage 
of initial body weight on day 0. *P < .05. C. Macroscopic disease score based on the presence of loose stool, bleeding and macroscopic inflammation determined on day 9 upon sacrifice. *P 
< .05. D. Assessment of colonic weight-to-length ratio upon sacrifice as an index of disease-related intestinal wall thickening. *P < .05. E. Representative histological sections of the mouse 
colon upon sacrifice and histological grading of colonic colitis scores. IMSCs decrease colitis activity in TNBS-treated mouse colons.  F. CD3-positive T-cells in vivo. Representative colon sec-
tions stained with anti-CD3, revealing T lymphocytes. Magnification, 20x. CD3-positive T-cells expressed as the ratio of CD3 relative to hematoxylin counterstain.
IMSCs alter cytokine profiles in colon homogenates
To investigate the effect of (I)MSC treatment on immunomodulatory 
profiles, we analyzed cytokine concentrations in colon homogenates. As 
previously described, distinct cytokine patterns were observed in DSS- and 
TNBS-induced colitis models.26 In both models, TNF-α and IL-6 levels 
were significantly elevated, reflecting ongoing general inflammation. Human 
and mouse IMSC treatment reduced TNF-α and IL-6 levels, while MSC 
treatment had no effect (Figures 7B and 7C).  Acute DSS-induced colitis  is 
mainly mediated by the innate immune system and results in a strong 
colonic induction of IFN-γ. Furthermore, IL-17A has been shown to be a 
pathogenic cytokine during DSS-induced colitis, as IL-17A knockout 
animals show an attenuated decrease in body weight as well as decreased 
disease activity.27 Indeed, IFN-γ and IL-17A expression were both 
increased during induction of DSS colitis (Figures 7D and 7E, left panels). 
Human MSC administration did not alter IFN-γ and IL-17A levels. In 
contrast, IMSC administration reduced both IFN-γ  and IL-17A expression 
essentially to the levels seen in control (non-induced) animals, consistent 
with the decrease in colonic inflammation observed in these mice. 
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Figure 7. IMSCs decrease systemic and local inflammatory responses in experimental colitis 
models. Serum and protein extracts were obtained from the colons at the acute phase of 
disease (day 9), and cytokine levels were measured. Data are presented as mean ± SEM; n=11 
mice per group; *P < .05, **P < .005. A. Serum amyloid A (SAA) levels were measured by 
ELISA and found to be reduced in mice with TNBS-induced colitis after IMSC treatment.  B-G. 
Cytokine levels of TNF-α, IL-6, IFN-γ, IL-10, IL-17A and IL-4 in colon homogenates of DSS- 
(left) and TNBS-induced (right) mice.
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TNBS-induced colitis is T-cell-mediated and mainly driven by a Th1 
response.28, 29 In this model, a lack of IL-17 signaling results in a more 
severe disease phenotype, likely due to uncontrolled induction of Th1 
responses.30 Interestingly, treatment of TNBS colitis  with mouse IMSCs 
resulted in the induction of IL-17 (Figure 7E, right panel) as well as IL-4 
(Figure 7G, right panel), indicating induction of Th2 and Th17 responses, 
respectively. These responses may inhibit Th1 skewing and thereby Th1-
driven pathogenesis as well. In addition, an increase in colonic IL-10 levels 
was observed, suggesting the presence of an active immunoregulatory 
component (Figure 7F, right panel).
IMSCs migrate to sites within the diseased intestine
Previously, MSCs were thought to specifically migrate to sites of tissue 
damage or inflammation.31 However, in these studies the focus was 
primarily on specific tissues of interest and the number of MSCs present at 
those sites in relation to the total number of MSCs administered was not 
correlated. We therefore administered human MSCs and IMSCs 
radiolabeled with technetium-99m to both control animals and animals 
with established colitis. The biodistribution data show that at 24 hours 
post-injection, the majority of radioactivity was present in the kidneys, 
urinary  bladder,  and  a  small  portion  in  the  liver (Table 1). Of note, we 
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Mean SEM Mean SEM Mean SEM Mean SEM
Colon 0.19 0.08 0.19 0.09 0.13 0.05 0.26 0.11
Coecum 0.15 0.06 0.1 0.05 0.1 0.05 0.19 0.09
Small intestine 1.24 0.51 1.58 0.71 0.61 0.25 2.48 1.01
MLN 0.12 0.05 0.19 0.09 0.13 0.06 0.1 0.05
Spleen 0.74 0.3 1.01 0.45 0.7 0.31 0.58 0.26
Kidney 8.22 3.35 10.09 4.51 5.13 2.09 7.63 3.11
Heart 0.09 0.01 0.03 0.02 0.01 0.01 0.04 0.02
Lungs 0.2 0.08 0.14 0.07 0.15 0.06 0.15 0.06
Liver 3.17 1.29 4.53 2.03 1.89 0.77 2.58 1.05
Femur 0.05 0.02 0.05 0.02 0.03 0.01 0.03 0.01
No colitis Colitis
MSC IMSC
No colitis Colitis
Table 1. Biodistribution of 99mTc-labelled human (I)MSCs 24 hrs after injection in healthy controls (no colitis) and DSS-treated (colitis)  mice. All data are presented as the % (mean ± SEM) 
of the total injected dose (ID) per gram of excised organ.
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Figure 8. Human IMSCs migrate to the inflamed intestine. A. Overlay images of 99mTc scintigrams and macroscopic photos of various organs 
excised from diseased mice. 99mTc-labeled human IMSCs were injected intraperitoneally on day 7 of DSS experiments, and organs were 
excised, photographed and scanned 24 hrs after injection. B. Radioactivity distribution in various tissues was calculated as the mean ± SEM 
percentage of the total  injected dose of radioactivity per gram of tissue (%ID/g). Data from two experiments (n=3 per group/experiment) 
were pooled and expressed as a ratio over MSC migration in control  mice, which was set to 1. *P < .05, colitis (DSS) versus no colitis 
(healthy control). C. Changes in mRNA abundance after 6 days of MSC treatment with IFN-γ as determined by microarray analysis. This 
heat map shows 21 molecules involved in cell migration. Green indicates down-regulation and red indicates up-regulation. Each column 
represents a single microarray analysis. Column 1, 2, 3, and 4 represent unstimulated MSCs of donor A, B, C and D, whereas columns 5 -8 
represents IFN-γ stimulated MSCs of the same donors A, B, C and D, respectively.
found radioactivity across a wide array of tissues, arguing against a highly specific trafficking of MSCs (Figure 
8A). Strikingly, when we compared cell trafficking under steady state conditions and during inflammation, we 
observed a clear difference between MSCs and IMSCs. IMSC migration to the intestine was significantly 
increased during colitis induction, whereas MSC distribution was unaffected, suggesting that IMSCs gain homing 
potential to sites of inflammation (Figure 8B).
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IFN-γ pretreatment alters expression of trafficking molecules
In order to examine more elaborately the mechanisms involved in the 
altered biodistribution of IMSC, gene expression profiles were generated 
from both MSC and IMSC. As expected, a large number of IFN-γ 
regulated genes was induced after treatment, including human leukocyte 
molecules and IDO (data not shown). We then focused on molecules 
associated with cell migration and adhesion. As has been described 
previously,6 IFN-γ treatment of MSCs resulted in upregulation of a number 
of pro-inflammatory chemokines (Figure 8C). Chemokine receptor 
expression however, did not change dramatically after 6 days of treatment, 
with the exception of an increased level of CXCR7. This suggested that 
treatment with IFN-γ does not result in profound changes in chemokine 
responsiveness of the MSCs and that this may not be the underlying cause 
of the altered trafficking observed. In contrast, the expression pattern of 
adhesion molecules was strikingly altered in IMSCs compared with MSCs 
from the same individual. Expression of a number of integrins was 
decreased, including ITGA10, ITGA11, ITGAE and ITGAV. In contrast, 
lectins LGALS3BP and LGALS9 were increased, as was ADAM15, a matrix 
metalloproteinase also involved in adhesion of cells to epithelium. 
DISCUSSION
MSCs can be used as a potential treatment for various immune disorders. 
Early phase I-II studies reported that MSCs are a safe and feasible 
treatment option in humans,16,32 and trials are ongoing to demonstrate 
clinical efficacy. Exact treatment dose, timing and frequency of 
administration, as well as the optimal source of MSCs, are currently under 
investigation. In addition, many in vitro and animal studies are performed to 
further elucidate the mechanism of immune modulation by MSCs.
Recent studies demonstrated that the immunosuppressive ability of MSCs 
is not intrinsic but instead induced by proinflammatory cytokines.6 
Exposing MSCs to inflammatory signals was found to significantly 
potentiate the immunosuppressive effects of MSCs on T-cells, monocytes/
macrophages and dendritic cells (DCs).7, 9, 33, 34 These data were further 
validated in vivo using animal models, where IFN-γ pretreatment improved 
MSC efficacy for the treatment of GvHD.9 Here, we demonstrate that 
IFN-γ stimulation potentiates MSCs to provide an effective treatment for 
both DSS- and TNBS-induced colitis, two experimental models for 
inflammatory bowel disease IBD.
Previous research revealed beneficial effects of MSCs on experimental 
colitis.35, 36 In these model systems, the therapeutic effect was mediated, at 
least in part, by suppression of inflammatory cytokines/mediators, 
increased infiltration of regulatory T-cells, and expression of the anti-
inflammatory cytokine IL-10.37 Although the MSCs used in these studies 
were not pretreated with IFN-γ, it is possible that they were activated in 
vivo, as MSCs were administered after the onset of inflammation. The 
proinflammatory environment in experimental colitis is comprised of an 
influx of mononuclear cells and high levels of TNF-α and IL-6. Both TNF-
α  and IFN-γ  treatment of MSCs induced IDO expression.33 Since only 
IMSCs are efficacious in the prevention of DSS-induced colitis, one could 
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speculate that at time of MSC injection (on day 0), the negligible levels of 
proinflammatory cytokines were insufficient to activate MSCs and initiate 
MSC-induced suppression. In fact, the absence of a protective effect of 
MSCs derived from fat tissue injected one day or one week prior to DSS 
colitis induction was recently described.35 
As IFN-γ is known to upregulate both MHC class I and II genes,22-25 it 
would be important to determine whether this upregulation makes cells 
more susceptible to rejection in an immune-competent host, particularly in 
the case of allogeneic cells. However, we administered both human and 
mouse (I)MSCs to immunocompetent mice and did not observe any 
apparent induction of immunologic responses. In vitro, pre-treatment of 
MSCs by IFN-γ does not enhance T-cell proliferation. On the contrary, 
PBMC proliferation is significantly inhibited at lower PBMC:(I)MSC ratios 
compared to untreated MSCs. Furthermore, systemic levels of the acute 
phase protein SAA were not increased by administration of IMSC. 
Similarly, in previous studies,35-39 positive treatment effects of human MSCs 
in experimental disease models was observed without apparent graft 
rejection, attributed to the inherent capacities of MSCs to reduce 
inflammatory cell infiltration, down-regulate inflammatory cytokine 
production, regulate immune tolerance by increasing the production of 
anti-inflammatory cytokines (e.g., IL-10) and promoting the generation/
activation of Tregs. Nevertheless, dedicated studies into the immunogenic 
status of (I)MSC are required to formally exclude induction of unwanted 
immune responses and to determine potential for clinical application. 
MSCs have been described to distribute broadly following systemic 
infusion (IV) and to be recovered from injured tissues such as skin, muscle 
and gut.31, 40 In agreement with this, using 99mTc-labeling, we also found 
activity in almost all tissues after intraperitoneal administration of human 
(I)MSCs. Interestingly, when focusing on the intestines specifically during 
colitis, enhanced migration of IMSCs but not MSCs was seen. Recently, Ko 
et al. demonstrated that enhancing binding of MSCs to adhesion molecule 
VCAM-1 (vascular cell adhesion protein) enhances their migration to the 
inflamed colon. Strikingly, only under these conditions, MSCs had a 
curative effect.41 These results are similar to those obtained by us in the 
present study as we show that MSC homing to the intestines is 
upregulated after IFN-γ stimulation and that only IMSCs were able to 
alleviate colitis symptoms. However, even under inflammatory conditions, 
only a small proportion of IMSC can be detected in the intestine, 
suggesting that additional mechanisms of immune suppression may be 
active. 
Previous studies have shown that IFN-γ primed MSCs secrete pro-
inflammatory chemokines, resulting in the recruitment of T-cells.6 Our 
study corroborates these findings and also points out the need for MSC–
T-cell proximity in order to achieve potent immunosuppression. Also in 
agreement with previous literature, we did not observe much alteration in 
chemokine receptor expression. However, a clear alteration was seen in 
the pattern of adhesion molecule expression. Most strinkingly, a number of 
integrins was downregulated, while various lectins were upregulated. In 
addition, ADAM15 expression was increased, which has been associated 
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with increased adhesion of fibroblast-like cells. The molecule forms 
homotypic cell-cell interactions and is expressed in human intestinal 
epithelium, thereby being a possible targeting molecule to this site. In 
summary, the complete balance between adhesion molecule expressions is 
strongly altered by IFN-γ treatment. As this balance influences the 
likelihood of a cell trafficking to a certain location, these alterations may 
underlie the altered trafficking observed after IFN-γ stimulation. However, 
further studies will be required to evaluate the individual contributions of 
all differentially expressed adhesion molecules. 
CONCLUSION 
We conclude that IFN-γ potentiates MSCs to suppress inflammatory 
responses in experimental colitis models. We show that IMSCs inhibit Th1 
inflammatory responses, leading to reduced T-cell activation and less 
proinflammatory cytokine secretion, resulting in diminished mucosal 
damage in two pre-clinical colitis models. We hypothesize that preactivation 
of MSCs with IFN-γ could lead to a more rapid clinical response and a 
dose reduction of cells, which could have profound effects on current 
treatment development programs. 
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CHAPTER 6
Summary, discussion, and future perspectives
SUMMARY
Hematopoietic stem cell transplantation and mesenchymal stromal (MSC) 
cell therapy are currently under investigation as novel therapies for 
inflammatory bowel diseases (IBD). Hematopoietic stem cells are thought 
to repopulate the immune system and reset the immunological response 
to luminal antigens. MSCs have the capacity to differentiate into a wide 
variety of distinct cell lineages and to suppress immune responses in vitro 
and in vivo. Recent results from animal models and early human 
experience in graft-versus-host disease (GvHD) and also Crohn’s disease 
(CD) suggest that ex vivo expanded MSCs may have clinically useful 
immunomodulatory effects. The main goal of this  thesis was to study the 
safety, feasibility, and applicability of stem cell therapy in IBD.
Chapter 1 gives an overview on inflammatory bowel diseases and stem 
cell therapy. This introduction highlights the present knowledge on 
hematopoietic stem cells and mesenchymal stromal cells in IBD treatment. 
The focus is on the immunomodulatory characteristics of stem cells and 
application of these cells in experimental colitis models. Furthermore, an 
overview on clinical trials with stem cells in IBD is provided.
In Chapter 2 the long-term (4 to 6 years) outcome of hematopoietic stem 
cell therapy (HSCT) is presented. Three patients (two male, one female) 
with active severe Crohn’s disease intolerant or refractory to conventional 
therapies, including anti-TNF-α antibodies were planned to undergo 
autologous HSCT. All three patients successfully completed stem cell 
mobilization and two of them subsequently underwent conditioning and 
autologous HSCT with CD34+ cell selection. Treatment was well 
tolerated, with acceptable toxicity. Five and six years post-transplantation, 
these patients are in remission under treatment. The third patient went 
into remission after mobilization and therefore she decided not to 
undergo conditioning and HSCT transplantation. After a successful 
pregnancy she relapsed two years later. Since then, she suffers from 
refractory Crohn’s disease for which we are now reconsidering 
conditioning and transplantation. These observations suggest that 
autologous HSCT appears to be safe and can be an alternative strategy for 
Crohn’s disease patients with severe and therapy resistant disease. 
The aim of the clinical trial in Chapter 3 was to determine the safety and 
feasibility of autologous bone marrow derived MSC therapy in patients 
with refractory Crohn’s disease. To this extent ten adult patients with 
refractory Crohn’s disease (eight females/two males) underwent bone 
marrow aspiration under local anesthesia. Bone marrow MSCs were 
isolated and expanded and MSCs were tested for phenotype and 
functionality in vitro. Nine patients received 2 doses of 1-2x106 cells/kg 
bodyweight, intravenously, 7 days apart. MSCs isolated from Crohn’s 
disease patients showed similar morphology, phenotype and growth 
potential compared to MSCs from healthy donors. Impor tantly, 
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immunomodulatory capacity was intact, as these MSCs significantly 
reduced peripheral blood mononuclear cell proliferation in vitro. MSC 
infusion was without side effects, besides a mild allergic reaction probably 
due to the cryopreservant DMSO in one patient. Three patients showed 
clinical response 6 weeks post treatment, conversely three patients 
required surgery due to disease worsening. Our data imply that MSCs 
isolated from Crohn’s disease patients have similar characteristics 
compared to MSCs from healthy donors and that administration of 
autologous bone marrow derived MSCs appears to be safe and feasible in 
the treatment of refractory Crohn’s disease as no serious adverse events 
were detected during bone marrow harvesting and administration.
Previous studies showed that immunosuppressive drugs can be harmful to 
hematopoietic stem cells or endothelial progenitor cell proliferation, 
thereby affecting their functional capacities. Likewise, immunosuppressive 
agents used in the treatment of IBD might have an effect on MSC function 
and could, change the outcome of MSC therapy and affect safety. In 
Chapter 4, we therefore investigated the interaction between MSCs and 
immunosuppressive drugs frequently used in the treatment of IBD and 
concluded that in vitro, MSC phenotype and function are not affected by 
therapeutic concentrations of drugs commonly used in the treatment of 
IBD. These findings are important for the potential clinical use of MSCs in 
combination with immunomodulating drugs and anti-TNF-α therapy.
Recent data suggest that resting MSCs do not have significant 
immunomodulatory activity, but that the immunosuppressive function of 
MSCs has to be elicited by interferon-gamma (IFN-γ). In Chapter 5, we 
assessed the effects of IFN-γ prestimulation of MSCs (IMSCs) on their 
immunosuppressive properties in vitro and in vivo. To this end, we 
pretreated MSCs with IFN-γ and assessed their therapeutic effect in two 
experimental colitis models in mice. We found that mice treated with 
IMSCs (but not MSCs) showed a significantly attenuated development of 
induced colitis. IMSC-treated mice displayed an increase in body weight, 
lower colitis scores and better survival rates compared to untreated mice. 
In addition, serum amyloid A protein levels and local proinflammatory 
cytokine levels in colonic tissues were significantly suppressed after 
administration of IMSC. We also observed that IMSCs showed greater 
migration potential than unstimulated MSCs to sites within the inflamed 
intestine. In conclusion, we show that prestimulation of MSCs with IFN-γ 
enhances their capacity to inhibit inflammatory responses, resulting in 
diminished mucosal damage in experimental colitis. These data show that 
IFN-γ activation of MSCs increases their immunosuppresive capacities and 
importantly, their therapeutic efficacy in vivo.
DISCUSSION 
Despite the improvement in medical therapy of inflammatory bowel 
disease with the introduction of anti-TNF-α compounds, disease control 
remains hard to achieve in many patients. Adult stem cells are currently 
under investigation for a variety of inflammatory disorders. HSCT may be 
an effective treatment for IBD and can be successfully used as a last resort 
in an attempt to control debilitating disease. However, it is associated with 
significant morbidity and mortality related to chemotherapy. The use of 
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MSCs derived from either bone marrow or adipose tissue could be an 
alternative approach. If effective, the big advantage of the use of MSCs is 
the fact that this treatment does not involve conditioning chemotherapy. In 
the limited number of patients treated with MSCs in the last decade, few 
adverse events have been attributed to MSC administration. Although 
acute toxicity appears low, little is  known about long-term unwanted side 
effects. Potential hazards include the possibility of malignant 
transformation, ectopic tissue formation, and the possible xenogenic 
transmission of disease and antibody formation when fetal bovine serum 
(FBS) is added to the culture medium. Furthermore, questions remain to 
be addressed about the mechanism underlying the immunomodulating 
properties of MSCs and their in vivo survival after exogenous 
administration. Discrepancies in MSC isolation, source, and culture 
protocols, as well as  experimental conditions and timing of analysis can 
explain variation in obtained results and possibly will complicate the 
interpretation of future trial outcomes. 
FUTURE PERSPECTIVES 
A multicenter, prospective, randomized phase III study has been initiated by 
the European Crohn's and Colitis Organisation (ECCO) in collaboration 
with the European Group for Blood and Marrow Transplantation (EBMT) 
to evaluate the efficacy of HSC mobilization followed by high dose 
immune ablation and autologous stem cell transplantation versus HSC 
mobilization only. In the case of MSC therapy, the Royal Perth Hospital, 
Australia, has just launched a multicenter phase II trial in 20 patients to 
evaluate the safety and efficacy of weekly intravenous infusion for 4 weeks 
with allogeneic bmMSCs. The University Hospital La Paz in Madrid is 
performing a phase I/IIa trial on allogeneic MSCs derived from fat tissue in 
the local treatment of recto-vaginal fistula in CD. Finally, the LUMC is 
currently investigating the safety and preliminary efficacy of allogeneic 
bmMSCs in the induction of response for active fistulizing CD in a dose 
escalation study.
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HOOFDSTUK 6
Samenvatting, discussie en toekomstperspectieven
SAMENVATTING 
INFLAMMATOIRE DARMZIEKTEN
De ziekte van Crohn en colitis ulcerosa zijn beide chronische 
inflammatoire (ontstekingsachtige) darmziekten. In het Engels wordt 
hiervoor de term IBD (Inflammatory Bowel Disease) gebruikt. Beide 
ziektes kunnen op elke leeftijd voorkomen, eerste uitingen van de ziekte 
wordt meestal vastgesteld tussen het 15e en 30e levensjaar. Er zijn 
verschillende factoren die van invloed kunnen zijn op het ontstaan 
inflammatoire darmziekten. Factoren die een rol spelen, zijn onder andere: 
het immuunsysteem, erfelijkheid, bacteriën in de darm, stress en roken. 
Ons immuunsysteem (afweersysteem) beschermt ons lichaam tegen 
schadelijke indringers, zoals bacteriën en virussen. Bij inflammatoire 
darmziekten is het immuunsysteem overactief. Het valt onschuldig weefsel 
aan, met als gevolg is dat er ontstekingen ontstaan in de darm. 
Bij de ziekte van Crohn en bij colitis ulcerosa komen een aantal dezelfde 
klachten en symptomen voor, namelijk: buikpijn, diarree vaak met bloed en 
slijm, soms verstopping, bloedarmoede, vermoeidheid en gewichtsverlies. 
Het zijn chronische ziektes die periodes van rust (remissie) en ziekte 
(opvlamming) kent. Helaas zijn er nog geen medicijnen die de ziekte van 
Crohn of colitis ulcerosa kunnen genezen. Wel is het mogelijk om de 
ontstekingen te remmen en de klachten met behulp van medicijnen te 
onderdrukken. Ook moeten deze medicijnen voorkomen dat er nieuwe 
ontstekingen ontstaan. Soms is een operatie nodig, bijvoorbeeld als 
medicijnen niet voldoende helpen of als er een vernauwing of afsluiting 
van de darm ontstaat. 
STAMCELLEN
Stamceltherapie wordt momenteel onderzocht als nieuwe therapie voor 
inflammatoire darmziekten. In dit proefschrift worden twee verschillende 
stamcellen besproken, namelijk hematopoietische stamcellen (HSC) en 
mesenchymale stromale cellen (MSCs). 
Hematopoietische stamcellen HSC therapie wordt al veelvuldig toegepast 
om verschillende vormen van kanker te behandelen. Van HSC is bekend 
dat transplantatie van de cellen naar de patiënt het immuunsysteem als 
ware ‘resetten’ en hiermee het overactieve immuunsysteem remmen. 
Mesenchymale stamcellen Sinds een aantal jaar wordt er steeds meer 
onderzoek gedaan naar de mogelijkheid om verschillende ziekten te 
behandelen met MSCs. Uit onderzoek in het laboratorium is namelijk 
gebleken dat MSCs uit kunnen groeien tot verschillende weefseltypen en 
in diermodellen van immuunziekten (zoals IBD) ontsteking remmen. 
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SAMENVATTING 
Het belangrijkste doel van dit proefschrift was om de veiligheid, 
haalbaarheid en toepasbaarheid van stamceltherapie voor IBD te 
bestuderen.
Hoofdstuk 1 geeft een samenvatting van wat er al bekend is over HSC en 
MSC in de behandeling van IBD. De focus ligt op de immunomodulerende 
eigenschappen van stamcellen en geeft uitleg over de bevindingen in 
muismodellen van IBD. Ook wordt een overzicht gegeven van klinische 
studies die zich richten op stamcellen voor de behandeling van IBD.
In Hoofdstuk 2 worden de lange termijn (4 tot 6 jaar) resultaten van 
hematopoietische stamcellen therapie (HSCT) gepresenteerd. Drie 
patiënten (twee mannen, één vrouw) met actieve ernstige refractaire 
ziekte van Crohn, dat wil zeggen niet te behandelen met bestaande 
therapieën, kregen de mogelijkheid aangeboden een autologe HSCT te 
ondergaan. Bij een autologe stamceltransplantatie worden stamcellen uit 
het bloed van de patiënt zelf gebruikt. Dat gebeur t na een 
chemotherapiekuur gecombineerd met de toediening van een groeifactor. 
De goede stamcellen worden ingevroren terwijl de patiënt een intensieve 
behandeling met een hoge dosering chemobehandeling ondergaat om 
zieke cellen uit het lichaam te verwijderen. Na de behandeling worden de 
goede stamcellen weer teruggegeven om het lichaam te laten herstellen. 
Bij alle drie de patiënten werden met succes stamcellen uit het bloed 
verkregen. Twee van de drie patiënten ondergingen nadien de intensieve, 
hoge dosering chemobehandeling. De behandeling werd goed verdragen, 
met aanvaardbare bijwerkingen. Vijf en zes jaar na transplantatie, zijn deze 
patiënten in remissie onder medicijnen. De derde patiënt ging in remissie 
nadat stamcellen werden verkregen middels de chemotherapiekuur 
gecombineerd met de toediening van een groeifactor. Omdat zij 
klachtenvrij was, werd besloten in dit geval niet ook de hoge dosering 
chemobehandeling te geven. Na een succesvolle zwangerschap is twee jaar 
later de ziekte van Crohn weer opgevlamd en wordt de intensieve, hoge 
dosering chemobehandeling en autologe HSC-transplantatie alsnog 
overwogen. Deze resultaten suggereren dat autologe HSCT veilig is en een 
alternatieve strategie zou kunnen zijn voor patiënten met ernstige 
therapieresistente ziekte. 
Het doel van het klinische onderzoek in Hoofdstuk 3 was om de veiligheid 
en de haalbaarheid van autologe mesenchymale stromale celtherapie bij 
patiënten met refractaire ziekte van Crohn te bepalen. In deze studie 
ondergingen tien volwassen patiënten (acht vrouwen / twee mannen) een 
beenmergpunctie onder lokale verdoving. Uit het beenmerg werden MSCs 
geïsoleerd en opgekweekt. Deze MSCs werden getest op uiterlijke 
kenmerken en hun functionaliteit met behulp van proeven in het 
laboratorium. Negen patiënten kregen twee doseringen van 1-2 miljoen 
cellen per kilo lichaamsgewicht, intraveneus toegediend, zeven dagen na 
elkaar. Uit het onderzoek is gebleken dat MSCs geïsoleerd uit het 
beenmerg van patiënten met de ziekte van Crohn vergelijkbaar zijn qua 
groeisnelheid en uiterlijke kenmerken met MSCs van gezonde donoren. 
Een belangrijk resultaat was dat de MSCs van de patiënten ook 
ontstekingsremmende eigenschappen hebben. MSC-transplantatie gaf geen 
90    Hoofdstuk zes 
bijwerkingen, behoudens een licht allergische reactie op het invriesmiddel 
DMSO in één patiënt. Drie patiënten vertoonden klinische verbetering zes 
weken na de behandeling, echter drie andere patiënten hadden een 
operatie nodig omdat bij hun de ziekte activiteit verergerden. Onze 
gegevens laten zien dat MSCs van patiënten met de ziekte van Crohn 
dezelfde kenmerken hebben als MSCs van gezonde donoren. Daarnaast 
laat deze studie zien dat het toedienen van autologe MSCs veilig en 
haalbaar is in de behandeling van de ziekte Crohn; er zijn geen ernstige 
bijwerkingen geconstateerd tijdens het oogsten van de cellen uit het 
beenmerg en bij het intraveneus toedienen van de cellen bij de patiënt. 
In Hoofdstuk 4 hebben we onderzoek gedaan naar de interactie tussen 
MSC en de ontstekingsremmende medicijnen die veelvuldig in de 
behandeling van IBD worden gebruikt. Eerdere studies toonden aan dat 
bepaalde geneesmiddelen schadelijk kunnen zijn voor HSC en andere 
voorloper cellen. Onze hypothese was dat ontstekingsremmende 
medicijnen die gebruikt worden in de behandeling van IBD een effect 
zouden kunnen hebben op de functie van MSCs en daarmee de uitkomst 
van MSC-therapie zouden kunnen beïnvloeden. Uit het onderzoek is 
gebleken dat de eigenschappen en functie van MSCs niet worden 
beïnvloed door therapeutische concentraties van geneesmiddelen die veel 
worden gebruikt in de behandeling van IBD. Deze bevindingen zijn van 
belang voor de potentiële klinische toepassing van MSCs in combinatie 
met geneesmiddelen die worden toegepast in de behandeling van de 
ziekte van Crohn. 
Recent gepubliceerde data laten zien dat MSCs in rust geen significante 
immunomodulerende activiteit hebben, maar dat de ontstekingsremmende 
werking van MSCs moet worden uitgelokt door interferon-gamma (IFN-
γ). IFN-γ is een signaalstof en speelt een rol in de verdediging tegen 
virussen. In Hoofdstuk 5 onderzochten we het effect van voorstimulatie 
van MSCs met IFN-γ (de zogenaamde IMSCs) op de eigenschappen van 
MSCs. Daartoe hebben we MSCs voorbehandeld met IFN-γ en hun 
functie beoordeeld in twee experimentele muismodellen van 
darmontsteking (colitis). Wij vonden dat muizen behandeld met IMSCs 
(maar niet de muizen behandeld met ongestimuleerde MSCs) minder 
darmontsteking ontwikkelden. De muizen behandeld met IMSC toonden 
een toename in lichaamsgewicht, minder ziekte activiteit en een betere 
overleving in vergelijking met onbehandelde muizen. Daarnaast kwamen er 
minder ontstekingsstofjes vrij en hebben we geconstateerd dat IMSCs 
beter migreren dan niet-gestimuleerde MSC naar de ontstoken darm. Tot 
slot laten we zien dat voorstimulatie van MSCs met IFN-γ hun vermogen 
vergroot om ontstekingsreacties te remmen, wat heeft geresulteerd in 
verminderde mucosale schade in experimentele colitis. Dit hoofdstuk laat 
zien dat IFN-γ activatie van MSCs hun ontstekingsremmende capaciteiten 
verhoogd en daarmee hun therapeutische werkzaamheid in vivo versterkt.
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DISCUSSIE
Ondanks de verbetering in de medische behandeling van inflammatoire 
darmziekte met de introductie van nieuwe medicijnen (bijvoorbeeld anti-
TNF-α) blijft het moeilijk de ziekte onder controle te houden bij veel 
patiënten. Volwassen stamcellen worden momenteel onderzocht voor een 
verscheidenheid van inflammatoire aandoeningen. HSCT kan een 
effectieve behandeling zijn van IBD. Echter, deze behandeling gaat gepaard 
met een aanzienlijke morbiditeit en mogelijk sterfte ten gevolge van 
chemotherapie. Het gebruik van MSCs zou een alternatieve strategie 
kunnen zijn. Het grote voordeel van het gebruik van MSCs, in tegenstelling 
tot HSCT, is dat voor het verkrijgen van deze cellen geen chemotherapie 
hoeft te worden gebruikt. Uit een beperkt aantal studies blijkt dat er 
weinig bijwerkingen zijn toegeschreven aan MSC transplantatie. Hoewel de 
acute toxiciteit laag lijkt, is er weinig bekend over de lange termijn 
bijwerkingen. Potentiële risico's omvatten de mogelijkheid van maligne 
transformatie, het uitgroeien van weefsel op ongewenste plaatsten en 
mogelijke xenogene overdracht van de virussen of het vormen van 
antilichamen door het gebruik van kalf serum (foetaal bovine serum: FBS), 
dat wordt toegevoegd aan het kweekmedium. Bovendien moeten er nog 
veel vragen worden beantwoord over hoe de cellen werken en waar zij 
blijven in het lichaam nadat zij getransplanteerd zijn. Verschillen in de 
manier van MSC-isolatie en opkweekprotocollen, maar ook 
omstandigheden waarin experimenten worden gedaan kunnen variatie 
tussen verkregen resultaten van verschillende onderzoeksgroepen 
verklaren en de interpretatie van verkregen resultaten bemoeilijken.
TOEKOMSTPERSPECTIEVEN
Momenteel vindt er een multicenter, prospectieve, gerandomiseerde fase 
III studie plaats geïnitieerd door de European Crohn's and Colitis 
Organisation (ECCO) in samenwerking met de European Group for Blood 
and Marrow Transplantation (EBMT) naar de werkzaamheid van HSCT in 
de ziekte van Crohn. In het geval van MSC-therapie is  het Royal Perth 
Hospital, in Australië, onlangs gestart met een multicenter fase II studie bij 
20 patiënten om de veiligheid en werkzaamheid van wekelijkse 
intraveneuze infusies met allogene MSCs (MSCs afkomstig van een donor) 
te evalueren gedurende vier weken. Het Universitaire Ziekenhuis van La 
Paz in Madrid bezig met het uitvoeren van een fase I / IIa studie met 
allogene MSCs uit vetweefsel in de lokale behandeling van recto-vaginale 
fistels bij patiënten met de ziekten van Crohn. Tot slot wordt in het Leids 
Universitair Medisch Centrum (LUMC) momenteel de veiligheid en 
werkzaamheid van allogene MSCs voor de lokale behandeling van fistels in 
een dosis-escalatie studie geëvalueerd.
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5-ASA! ! 5-aminosalicylic acid
6-MP! ! 6-Mercaptopurine
atMSC! ! adipose tissue MSC
ATG! ! antithymocyte globulin
bmMSC!! bone marrow MSC 
CCMO! ! Central Committee on Research involving 
! ! Human Subject
CD! ! Crohn’s disease
CDAI! ! Crohn's disease activity index 
CDEIS! ! Crohn's disease endoscopic index of severity
CFU! ! colony forming-units
CRP! ! C-reactive protein 
DC! ! dendritic cell
DMSO ! ! dimethyl sulfoxide
DSS ! ! dextran sulfate sodium
EBMT! ! European Group for Blood and Marrow Transplantation
ECCO! ! European Crohn's and Colitis Organisation
FBS! ! fetal bovine serum 
gMSC! ! gingival MSC
G-CSF! ! granulocyte colony-stimulating factor
GvHD! ! graft-versus-host disease 
HGF! ! hepatocyte growth factor
HLA! ! human leukocyte antigen
HSC! ! hematopoietic stem cell 
HSCT! ! hematopoietic stem cell transplantation
IBD! ! inflammatory bowel disease
IDO! ! indoleamine 2,3-dioxygenase
IFN-γ ! ! interferon gamma
IL! ! interleukin
IMSC! ! IFNγ-stimulated mesenchymal stromal cell
iNOS ! ! inducible nitric oxidase synthase
i.p. ! ! intraperitoneally
LUMC! ! Leiden University Medical Center 
MHC! ! major histocompability complex 
MNC! ! mononuclear cell
MRI! ! magnetic resonance imaging
MSC! ! mesenchymal stromal cell
PBMC! ! peripheral blood mononuclear cell 
PGE2 ! ! prostaglandin E2
TGF! ! transforming growth factor
TNBS! ! trinitrobenzene sulfuric acid
TNF-α! ! tumor necrosis factor-α
TSG-6! ! tumor necrosis factor-inducible gene 6
UC! ! ulcerative colitis
RBC! ! red blood cells
TGFβ-1! ! transforming growth factor beta 1
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